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Abstract 
Breast cancer is one of the major causes of death in South Africa. About 1 in 29 
South African women are at risk of developing this type of cancer in their 
lifetime. The global incidence of breast cancer also increases annually with over 1 
million new cases diagnosed every year. Molecular diagnostic techniques such as 
qRT-PCR, Fluorescent In Situ Hybridization (FISH), Immunohistochemistry 
(IHC) and ELISA are used to diagnose breast cancer.  Some of these diagnostic 
techniques make use organic fluorophores as fluorescent reporter molecules. The 
principle of all these diagnostic techniques is reliant on the detection of molecular 
biomarkers that are associated with the disease. In most cases these molecular 
biomarkers are DNA, RNA or proteins that are up-regulated in response to or as a 
result of the disease.  
 
The first aim of this study was therefore to identify membrane proteins that are 
up-regulated in cancers that can potentially be used as biomarkers for the 
detection of breast cancer. The second aim of this study was to investigate the 
application of quantum dots in the development of a molecular diagnostic test that 
can detect a breast cancer biomarker. 
 
The most commonly used method to identify molecular biomarkers for diseases 
have traditionally been gene expression analysis using technologies such as DNA 
microarray. These technologies have certain limitations and have therefore not 
been very successful in identifying useful disease biomarkers. Biomarker 
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discovery by proteomics can overcome some of these limitations and is 
potentially a more suitable method to identify molecular biomarkers for breast 
cancer. 
 
In this study proteomics in combination with Stable Isotope Labelling with Amino 
Acids in Cell Culture SILAC was used to do a comparative analysis of the 
expression levels of membrane proteins present in a human breast cancer cell line 
(MCF-7) derived from a breast cancer patient and a human breast cell line (MCF-
12A) derived from a healthy individual. This led to the identification of the 
transmembrane protein, GFRA1 as potential new biomarker for breast cancer. 
This study showed that this protein is over expressed in MCF-7 cells as compared 
to MCF-12A cells and that it is also highly expressed in the myoepthelial cells of 
the milk ducts of breast cancer patients. 
 
This study also demonstrates the use of molecular beacon technology to develop a 
DNA probe for the detection of cDNA encoding the CK19 gene, which is a 
known biomarker for breast cancer. In the development of this probe, quantum 
dots were used as the fluorescence reporter. This molecular beacon probe was able 
to demonstrate the over expression of CK19 in MCF-7 cells. This study shows 
that this technology can potentially be used as a diagnostic test for breast cancer 
and since quantum dots are used in the development of these molecular beacon 
probes, this diagnostic test can potentially facilitate the development of multiplex 
detection systems for the diagnosis of breast cancer. Molecular beacon technology 
can potentially also be used to detect novel biomarkers such as GFRA1. 
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CHAPTER 1 
 
1.1 Cancer 
Cancer is a disease caused by the uncontrollable multiplication of groups of cells 
that arise from genetic alterations that affect tightly controlled regulatory systems 
required for the control of cell growth (Pietras et al., 2010). All cancers arise as a 
result of changes that have occurred in the DNA sequence which results from a 
stepwise accumulation of genetic alterations within a cell (Stratton et al., 2009). 
These alterations lead to abnormal proliferation and expansion, and ultimately 
invasion of surrounding tissues (Nass et al., 1997, Antoniou et al., 2003). 
 
Six key features or hallmarks characterize cancer cells (Hanahan et al., 2000). 
These hallmarks are 1) cancer cells can stimulate their own growth, 2) cancer cells 
can bypass growth suppressors, 3) cancer cells can evade apoptosis, 4) cancer 
cells can multiply indefinitely, 5) cancer cells develop excessive angiogenesis 
systems and 6) cancer cells can invade surrounding tissues (Hanahan et al., 2000).  
Cancer pathophysiology can either be hereditary or triggered by environmental 
factors such as smoking, diet and exposure to ultraviolet radiation (Croce 2008). 
Genetic mutations in proto-oncogenes and tumour suppressor genes can lead to 
cancer (Croce 2008). Proto-oncogenes are involved in cell signalling processes 
under normal physiological conditions. However, these genes can be activated by 
genetic mutations to become oncogenes, which contributes to the development of 
cancer. Oncogenes can also be activated by the DNA de-methylation, which could 
lead to a dosage effect, i.e. producing an additional functional copy of the gene, 
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which in turn can also lead to cancer growth (Stratton et al., 2009, Muthusamy et 
al., 2010). Several oncogenes have been identified, such as growth factor 
receptors common in breast cancer, for example human epidermal growth factor 2 
(HER-2/neu), Myelocytomatosis Viral Oncogene Homolog (c-Myc), Rat sarcoma 
(RAS), Mitogen-activated protein kinase (ERK) and (B-cell lymphoma 2) Bcl-2 
(Croce 2008).  
 
Tumour suppressor genes suppress tumour formation. These genes inhibit cell 
proliferation and cell division during the cell cycle allowing time for the 
correction of mistakes that may occur during DNA replication (Chen et al., 1998).  
However, mutations can inactivate the tumour suppressor genes, which can lead 
to the development of cancer. Tumour suppressor genes can also be inactivated by 
DNA methylation and histone deacetylation to render them non-functional (Deng 
et al., 2000). Examples of tumour suppressor genes are Retinoblastoma gene 
(RB), Protein of 53 kilodaltons (kDa) (p53) and INK4a is a protein of 16 kDa 
(p16
INK4a
) (Sherr 2004), breast cancer 1(BRCA1) and breast cancer 2 (BRCA2) 
(Hall et al., 1990).  
 
Cancer is considered to be an important global health problem because it affects 
millions of people all over the world (Xue et al., 2008). It is predicted that cancer 
will become the main cause of morbidity and mortality in the coming decades all 
over the world (Bratu et al., 2011). Cancer accounts for more than six million 
deaths a year worldwide, with ten million new cases are diagnosed each year (Xue 
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et al., 2008). Studies showed that in 2008, an estimated 196,3 million healthy life-
years were lost worldwide because of cancer (Soerjomataram et al., 2012).  
 
In the United States of America (USA) alone, a quarter of the mortality tolls are 
attributed to cancer (Peng et al., 2010). Cancer is recognised as the second leading 
cause of death in USA after heart diseases (American Cancer Society. 2014). In 
2014, approximately 585,720 American people died from cancer (American 
Cancer Society. 2014). One in three women and one in two men in the USA are 
expected to develop cancer in their lifetime (Medley 2007). The total cancer 
incidence in the USA recorded between 2004 and 2008 were 1,638,910 cases 
(Siegel et al., 2012). This included 226,870 cases for breast cancer, 12,170 cases 
for uterine cancer, 143,460 cases for colon and rectum cancer and 241,740 cases 
for prostate cancer (Siegel et al., 2012). The most common cancer among women 
world wide is breast cancer (Agarwal et al., 2009), which is also the second 
leading cause of cancer deaths in women (Gauger et al., 2014). Therefore breast 
cancer is considered one of the most important diseases amongst women 
worldwide (Gast et al., 2009). 
 
Cancer is also a major problem in developing countries and the second most 
common cause of death (Xue et al., 2008). Although some statistics are available 
for South Africa, the incidence of cancer in African countries is not very well 
studied and documented. The 2008 South African National Cancer Registry 
reported that the top cancers in South Africa was cancers of the breast, cervical, 
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bladder, stomach, oesophagus and colorectal (Cancer Association of South Africa. 
2014). 
 
1.2. Breast cancer  
The female breast consists of lobes, lobules and milk ducts (Figure 1.1). The 
breast consists 15 to 20 lobes, each one made up of many smaller lobules, which 
are the milk producing mammary glands. The lobules are connected through milk 
ducts. The breast ducts are composed of the basement membrane and a layer of 
luminal epithelial and myoepithelial cells, while the surrounding stroma include 
leukocytes, fibroblasts, myofibroblasts, and endothelial cells (Polyak 2007). 
Breast cancer is a malignant disease that originates from cells in the breast tissue. 
One model for breast cancer suggests that the myoepithelial cells are genetically 
altered causing a decrease in the number of these cells, while the number of 
stromal fibroblasts, myofibroblasts, lymphocytes, and endothelial cells increases. 
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Figure 1. 1: The anatomy of the female breast. The lobes, lobules and ducts, are indicated 
(Winslow. 2011).  
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In terms of histology, therapeutic response and patient outcomes, breast cancer is 
considered a highly heterogeneous disease (Prat et al., 2011, Network 2012). 
Breast cancer is an adenocarcinoma that is classified as either a ductal or lobular 
carcinoma (Hammer et al., 2008) since these two structures are the primary 
origins of the malignancy. Most breast cancer cases arises from luminal epithelial 
cells (Fang et al., 2009) which makes up the milk production glands and ducts that 
connect to the nipple (Prat et al., 2011, Network 2012). Ductal and lobular 
carcinoma can be further classified into other pathological subgroups such as in 
situ or invasive (Hammer et al., 2008). 
 
1.2.1 Prevalence of breast cancer  
Breast cancer is the second leading cause of death after lung cancer in the USA 
(Jemal et al., 2007) and remains one of the leading causes of cancer-related deaths 
in the Western world (Kuhl et al., 2007). It is responsible for over 500 000 deaths 
per year worldwide (Königsberg et al., 2011). The incidences of breast cancer is 
also increasing in developing countries such as South Africa (Agarwal et al., 
2009). One in nine women are at risk of developing breast cancer (Callesen et al., 
2008). 
 
In the USA, breast cancer affected about 232,620 women and men in 2011 and 
was responsible for 39,970 deaths in the same year (Siegel et al., 2011). In 2014, 
it was estimated that about 232,670 new cases of breast cancer were diagnosed 
among the women in the USA, making it the most frequently diagnosed cancer in 
women (Siegel et al., 2014). In Australia, about 2 % of the women between the 
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ages of 20 and 34 years and 11 % of women between the ages of 35 and 44 years 
are affected by breast cancer (Hickey et al., 2009). It was reported by Ferlay et al. 
(2007) that breast cancer accounted for 429,900 cases of cancer in European 
women in 2006 (Ferlay et al., 2007). In South Africa, breast cancer is the most 
common type of cancer amongst women, affecting about 16.6 % of women 
(Vorobiof et al., 2001). According to the 2008 South African National Cancer 
Registry, the number of the female breast cancer patients in the different 
population groups were as follows: 2,884 cases amongst blacks, 1,976 cases 
amongst whites, 834 cases amongst coloureds and 330 cases amongst Asians 
(Cancer Association of South Africa. 2015). 
 
1.2.2 Types of breast cancer  
Upon diagnosis, breast cancer is classified primarily by the histological 
appearance of the cancer cells. There are two main types of breast cancer: 
carcinoma in situ and invasive (infiltrating) carcinoma. These two types of breast 
cancer will be briefly described below. 
 
1.2.2.1 Breast carcinoma in situ  
Breast carcinoma in situ (CIS) is further classified into either ductal or lobular 
CIS (Figure 1.2) based on cytological features (Malhotra et al., 2010). Ductal 
carcinoma in situ (DCIS) is one of the most common types of non-invasive 
cancer. This type of cancer is defined when the cancer cells are present within the 
ducts, but have not yet spread and infiltrate the surrounding breast tissues 
(Bravaccini et al., 2013). DCIS affects the basement membrane of the breast 
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myoepithelium. The neoplastic cells proliferate and accumulate within the milk 
ducts. In the healthy breast, the ducts have a single epithelial layer, however, 
during development of DCIS neoplastic cells grow uncontrollably into a lesion 
resulting in multiple layers that accumulate inside the ducts. The breast stroma 
including the extracellular matrix, lymphatics, blood vessels, stromal cells, 
immune cells and fat cells can either promote or suppress the carcinogenic process 
by responding to secretory signals due to oxidative stress and nutrient deprivation 
that arise from the tumour cells accumulating within the duct (Espina et al., 2011). 
If not treated, DCIS may progress at a later stage to invasive ductal carcinoma 
(IDC), but the mechanism of this transition is not yet well understood (Sue et al., 
2013).  
 
1.2.2.2 Invasive (or infiltrating) carcinoma 
Like DCIS, IDC originates from the milk ducts then spreads through the walls of 
the ducts to surrounding breast tissues (Johnson et al., 2012). IDC is the most 
common type of invasive breast cancer, accounting for 72 to 80 % of all invasive 
breast cancers (Arps et al., 2013) and accounts for 8 to 14 % of all breast cancer 
cases (Malhotra et al., 2010). Invasive carcinoma is divided into six categories, 
that includes tubular, ductal lobular, infiltrating ductal, mucinous, medullary and 
invasive lobular carcinoma (ILC) (Figure 1.2). 
 
ILC also known as infiltrating lobular carcinoma is a major invasive tumour type 
that originates from the lobules and compared to IDC is more likely to be positive 
for hormone receptors (Arpino et al., 2004). ILC is characterized by a general 
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thickening of an area of the breast, usually the section above the nipple and 
toward the arm. This type of cancer is difficult to visualize by mammography 
(Cao et al., 2012), and if not treated within 3 years after disease diagnosis, the 
diseased cells can spread to different parts of the body such as the bones, lungs, 
liver and brain (Weigelt et al., 2005, Fernandez et al., 2013, Switzer et al., 2014). 
 
 
 
 
 
Figure 1. 2: The classification of breast cancers. This classification based on Nuclear 
Pleomorphism, Glandular/Tubule Formation and Mitotic (Malhotra et al., 2010).  
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Distant metastasis of the cancer is common in breast cancer patients during the 
late stages of the disease (Weigelt et al., 2005). Distant organ invasion begins 
when the primary subpopulations of breast tumour cells acquire metastatic ability 
through acquired somatic mutations. These mutations determine the site where the 
tumour cells are likely to invade. Several prognostic markers have been studied to 
identify breast cancer patients at risk of disease metastasis; the markers include 
the tumour size, angioinvasion, gene and protein profiling. For instance, patients 
with tumours that are 2-5 cm in size and have tumour emboli in more than three 
blood vessels are at a higher risk of metastasis (Weigelt et al., 2005). 
 
Metastasis of cancer into other tissues or organs occurs when the cancer cells 
migrate into the circulatory blood system and once arrested by capillaries of the 
distant tissues the cells invades the tissue and starts to proliferate and grow into a 
new tumour. The cancer cells are depended on angiogenesis to spread from its 
original location to other sites in the body and for a continuous supply of oxygen 
and nutrients to grow and multiply (Weigelt et al., 2005). 
 
The bones and the lungs are the primary targets in breast cancer metastasis 
(Weigelt et al., 2005). Once spread to the bones, the patients suffer from extreme 
pain and have increased risk of fractures (Jimenez‐Andrade et al., 2010). When 
the cancer cells get into the lungs, these patients can have difficulty with 
breathing, chest tightness, chronic cough, pleural effusion, loss of appetite and 
weight loss (Temel et al., 2007).  
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1.2.3 Breast cancer treatment  
1.2.3.1 Surgery  
Surgery is usually the first line of treatment, however, mandatory radiation or 
chemotherapy and hormonal therapy is required thereafter (Collins et al., 2011, Li 
et al., 2011). The complete resectioning of the cancerous tissue is a standard 
approach to treat breast cancer (Ziogas et al., 2009). A large number of breast 
cancer patients undergo mastectomy, a surgical procedure that involves the 
removal of the whole breast (Coopey et al., 2013). In the event that the patient is 
diagnosed at an early stage, removal of the cancerous tissue as opposed to the 
whole breast is preferred (Osman et al., 2013). This may be achieved using breast-
conserving surgery such as lumpectomy, partial mastectomy and modified radical 
mastectomy. Lumpectomy is a type of surgery that entails the removal of a 
tumour (lump) and some of the normal tissue surrounding the tumour (Sabel et 
al., 2009). Partial mastectomy is a procedure used in patients with invasive breast 
cancers. It entails the removal of a section of the breast that is cancerous together 
with some of the normal tissue surrounding it (McCahill et al., 2012). Whereas 
modified radical mastectomy entails removing the entire breast and its tissues 
(Loukas et al., 2011). Current strategies employed in the treatment of breast 
cancer are associated with adverse health effects.  
 
Sentinel lymphatic drainage and axillary node dissection  
Lymphatic drainage and dissection is often performed in breast cancer patients 
when the cancer has metastasized into sentinel lymph node (SLN) and axillary 
lymph nodes (ALN) (Mansel et al., 2006, Del Bianco et al., 2008). Lymphatic 
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drainage follows post surgery to relieve chronic lymphatic oedema in patients; the 
technique uses manual massage to redirect the blood flow towards healthy areas 
(Martín et al., 2011). 
 
The SLN is the first lymph node to receive lymphatic drainage from a tumour and 
is the most likely route a primary tumour will migrate from (Mansel et al., 2006, 
Del Bianco et al., 2008). The ALN dissection is usually performed in patients 
with invasive breast cancer. It is sometimes used as a prognostic factor to 
determine the stage of the breast cancer (Smeets et al., 2013). This procedure 
however, has been associated with short and long term side effects, such as in 
lymphedema, nerve injury, and shoulder dysfunction (Krag et al., 2010). SLN 
biopsy is considered an accurate method for the detection of axillary metastasis in 
patients diagnosed with breast cancer at an early stage (Jonjić et al., 2012).  
 
1.2.3.2 Radiation therapy 
Irradiation therapy can reduce the risk of cancer recurrence in patients who had 
breast-conserving surgery followed by radiotherapy (Buchholz 2009). This in turn 
can reduce the mortality of breast cancer after breast-conservation surgery. A 
drawback of irradiation therapy is the toxic effects of radiation, but this is 
depended on the course and the dose of radiation (Whelan et al., 2010). 
 
Radiation therapy can also increase the rate of cardiovascular disease in ageing 
women (Wood et al., 2001). This therapy should also not be given to patients 
suffering from systemic lupus erythematosus, scleroderma and pregnant women, 
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especially during the first trimester of their pregnancy (Buchholz 2009, Whelan et 
al., 2010). 
 
1.2.3.3 Chemotherapy  
Chemotherapy is a treatment administered to cancer patients, which is aimed at 
killing rapidly multiplying cells, which include cancer cells (Smith et al., 2002). 
Chemotherapy is considered to be useful treatment for older women, however, the 
side effects associated with chemotherapy, such as vomiting, hair loss and nausea 
has a negative impact on the patients’ quality of life (Niikura et al., 2013). 
Therefore, chemotherapy is beneficial to premenopausal women suffering from 
breast cancer (Dellapasqua et al., 2005). Niikura et al. (2013) reported that 
previous studies found chemotherapy, as an adjuvant therapy, in women with 
breast cancer as the preferred treatment. However, younger women preferred 
chemotherapy as compared to older women (Niikura et al., 2013). Recently 
neoadjuvant therapy has been considered as an approach for the treatment of 
breast cancer in the early stages of the disease in order to increase the rate of 
breast-conserving therapy and also as a means to reduce the extent of surgery 
(Gampenrieder et al., 2013).  
 
1.2.3.4 Endocrine therapy  
Endocrine therapy (hormone therapy) reduces the disease–related mortality and 
improves disease-free survival in patients with an early stage of breast cancer 
(Romond et al., 2005). Niikura et al. (2013) reported that endocrine therapy as 
opposed to chemotherapy was the preferred treatment option (Niikura et al., 
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2013). For women with hormone receptor-positive breast cancer, adjuvant 
endocrine therapy is often advised, such as tamoxifen treatment which reduces 
breast cancer recurrence and mortality in patients with hormone receptor-positive 
cancer (Connor et al., 2013).  
 
1.2.3.5 Targeted therapy  
Targeted therapy refers to a drug or other substance that is directed to cancer-
specific markers using molecules that will recognize the cancer cells; and in so 
doing block their growth and spread without harming the healthy cells (Nahta et 
al., 2006). Some of the targeting moieties used in the treatment of breast cancer 
include monoclonal antibodies, tyrosine kinase inhibitors and poly (ADP-ribose) 
polymerase (PARP) inhibitors. Several targeted therapies approved by the Food 
and Drug administration (FDA) include monoclonal antibodies such as 
trastuzumab (Herclon, Herceptin) and pertuzumab patients (Mohamed et al., 
2013). Both therapies block the action of the HER-2/neu growth factor, which is 
known to promote the growth of breast cancer cells. However, pertuzumab is used 
as a combinatorial therapy in metastasized breast cancer patients (Mohamed et al., 
2013). PARP is a group of enzymes encoded by the PARP1 gene that detects and 
interferes with DNA repair, and is involved in base excision repair and repairing 
of double stranded DNA breaks, which is also one of the most important aspects 
in the treatment of cancer (Weil et al., 2011, Davar et al., 2012). Tyrosine kinase 
inhibitors act by blocking tyrosine kinases, which plays a critical role in growth 
factor signalling (Arora et al., 2005). 
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1.2.3.6 Nanotechnology-based treatments for breast cancer  
Nanoparticles ranging in the sizes between 1 and 100nm have physicochemical 
properties that renders them useful in medicine (Yang et al., 2013). 
Nanotechnology has shown a great promise in the treatment and diagnosis of 
cancer. Nanomaterials capable of delivering chemotherapeutic agents directly to 
the breast cancer tissues bring hope in the fight against breast cancer. Due to their 
small size, nanoparticles have large surface area. Smaller nanoparticles have an 
increased loading capacity that can be manipulated for biological use. The 
nanoparticles can be used in multi-modal systems by attaching targeting, 
diagnostic and therapeutic agents. By targeting disease associated markers it is 
possible to minimize bystander effects to healthy tissues and increase drug 
efficacy at lower dosages (Tanaka et al., 2009, Tharkar et al., 2014).  
 
Nanotechnology-based strategies for breast cancer theranostics are under 
extensive study and development to overcome toxicity issues associated with 
conventional chemotherapeutic agents and to design early diagnostics assays. 
Nanoparticles as drug delivery agents can be personalised by targeting specific or 
diseased tissues, thereby reducing the dosage and frequency of drug treatment 
(Saadeh et al., 2014).  
 
In breast cancer diagnostics, magnetic nanoparticles (MNPs) and semiconductor 
nanoparticles are employed as contrast agents for the detection of primary and 
metastatic tumours at the molecular level and assess the disease stage (Ahmed et 
al., 2013). Detection of tumours that has accumulated the nanoparticles can be 
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achieved by traditional techniques such as MRI. Multiplexing is possible as 
different sized nanoparticles targeting different markers can be used at once to 
determine the position of the cancer (Ahmed et al., 2013) 
 
Furthermore, gold nanoparticles (AuNPs) have been widely studied for 
development of clinical diagnostic applications. The properties of AuNPs has 
shown great promise to be used in medical field to develop Point-of-care (POC) 
diagnostic systems for the specific detection of DNA and RNA sequences and 
immunoassays (Baptista et al., 2008). 
 
Another successful application of nanoparticles is the use of liposomes as cancer 
drug delivery vehicles. Liposomes are the first drug-carrying nano-carriers to 
reach cancer clinics (Markovsky et al., 2012). They are self-assembled closed 
colloidal structures composed of concentric phospholipid bilayers surrounding a 
central aqueous core (Parveen et al., 2012). They offer simultaneous loading of 
hydrophobic (non-polar molecules/drugs) into the lipid bilayer while hydrophilic 
(polar molecules/drugs) can be encapsulated in the aqueous core allowing a 
variety of therapeutic cargo (e.g. anti-cancer drugs, DNA, peptides, vaccines, 
enzymes, and imaging agents) to be loaded into this assembly (Perche et al., 
2013). They have been reported to be biocompatible, biodegradable, have low 
immunogenicity and excellent safety profiles in humans. It also offers unlimited 
therapeutic cargo loading, increased pharmokinetic and pharmodynamic abilities 
and it is relatively inexpensive for mass production. These factors make liposomes 
superior as nanoparticle carrier system for therapeutics. 
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The first liposomal drug to gain approval by the FDA in 1995 was Doxil or 
Caelyx (Perche et al., 2013), and has been used to treat a wide variety of advanced 
stage cancers such as ovarian cancer, metastatic breast cancer and AIDS-related 
Kaposi's sarcoma. Doxil is a PEGylated liposomal formulation of doxorubicin. 
Other commercialized phase III liposomal doxorubicin liposomes include: 
Myocet, LipoDox, Thermodox and DaunoXome. Drugs such as Vincristine 
(Marqibo), Paclitaxel (Lipusu and LEP-ETU), Cisplatin (Lipoplatin) have also 
been formulated in liposomes and are undergoing phase III clinical trials. 
 
1.2.4. Diagnostic methods for breast cancer  
1.2.4.1 Clinical diagnosis  
1.2.4.1.1 Breast self-examination  
Breast self-examination (BSE) is a screening method used by women to check for 
any irregularities in the breast tissue (Petro-Nustas et al., 2013). BSE is a physical 
examination of the breast using fingers to feel or detect any possible lumps in the 
breast tissue. This technique is simple and allows women to take charge of their 
own health (Harris et al., 2002). The American Cancer Society (ACS) 
recommended that women should familiarise themselves with what the normal 
state of the breast tissue and frequently check for any abnormalities by feeling the 
breast using the pads of their fingers (Evans, 2012).  
 
1.2.4.1.2 Mammography  
Mammography is a screening method that has shown to reduce mortality rates 
associated with breast cancer when followed up with more superior diagnostic 
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methods and treatment. With this screening approach it is especially women aged 
between 39 and 69 years that can benefit (Berg 2009, Brodersen et al., 2010, 
Nelson et al., 2009). In developed countries, mammography form part of general 
health services (Weedon-Fekjær et al., 2008). Screening rates vary between 
woman and appears to be linked to the level of the women’s education (Evans, 
2012). Screening rates in women without a tertiary education is lower as 
compared to women with tertiary education, which suggest that this is be linked to 
the women’s socioeconomic circumstances. 
 
Mammography is limited in that it isn’t sensitive enough to detect cancer in dense 
breast tissues (Evans, 2012). A small margin of false-negative and false-positive 
results has also been associated with mammography which might cause a delay in 
the diagnosis and treatment of breast cancer (Brodersen et al., 2010). It was also 
shown that mammography cannot detect all the breast cancer foci (Kuhl et al., 
2007). Pataky et al, (2013) carried out a comparative analysis on the cost 
effectiveness of Magnetic Resonance Imaging (MRI) versus mammography for 
breast cancer diagnosis in BRCA1/2 mutation carriers (Pataky et al., 2013). This 
study found that the cost of mammography is lower compared to MRI but that it is 
also less sensitive than MRI. 
 
1.2.4.1.3 Ultrasound  
Ultrasound (US) is widely available, inexpensive and generally well received by 
patients (Kelly et al., 2010). Breast US is primarily used to distinguish between 
solid masses and cysts in the breast (Nothacker et al., 2009). In developing 
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countries, US has become popular among lower level health centres (Gonzaga 
2010) and is more sensitive than mammogram especially in patients with dense 
breast tissue (Madjar 2010, Luparia et al., 2013). US are more superior to 
mammography when evaluating the tumour size (Keune et al., 2010) and is an 
low cost method for evaluating palpable breast cancer (Gonzaga 2010).  
 
1.2.4.1.4 Magnetic Resonance Imaging (MRI) 
MRI is a technique mainly used for the assessment of complex lesions found in 
women with a high risk of developing breast cancer (Warner 2011). MRI as a 
screening tool for breast cancer and has shown a higher degree of sensitivity as 
compared to mammography (Bryce et al., 2000, Saslow et al., 2007). It provides 
more information about the breast tissue vascularity that cannot be obtained from 
mammography (Liberman 2004). False-negative and false-positive results after 
MRI screening can be attributed to inherent technology limitations of MRI, 
human error and/or the patient’s characteristics (Saslow et al., 2007).  
 
1.2.4.2 Molecular diagnostic methods  
The molecular diagnosis of cancer is based on the detection of molecular changes 
that is associated with the disease and depends on the identification of biomarkers 
that is associated with these molecular changes. Biomarkers refer to molecules 
that are used as an indicator of the biological state, behaviour and function of the 
cells (Strimbu et al., 2010). Pathologically significant biomarkers include the 
expression or altered expression of genes and gene products, proteins and lipids 
(Nie et al., 2007). A number of different molecular diagnostic methods can be 
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used to evaluate the presence of such biomarkers in a patient sample. This 
includes techniques such as quantitative real time Polymerase Chain Reaction 
(qRT-PCR), enzyme-linked immunosorbent assay (ELISA), Fluorescent in situ 
hybridization (FISH) and Immunohistochemistry (IHC). For the purpose of this 
discussion, only FISH, IHC and qRT-PCR will be highlighted. 
 
1.2.4.2.1 Fluorescent in situ hybridization  
Fluorescent in situ hybridization (FISH) is a cytogenetic technique used to detect 
the physical location of specific gene or specific nucleic acid sequences (DNA or 
RNA) in intact chromosome and to assess if multiple copies of a specific gene or 
nucleic acid sequence (e.g. HER-2 gene for breast cancer) is present (Tanke et al., 
2005). Using fluorescence microscopy, FISH allows for the identification of 
chromosomal abnormalities for a given condition. This is based on the use of 
fluorescent probes having a complementary sequence to that of the target gene. 
Three probes are generally used in FISH, to detect either the whole-chromosome 
painting or repetitive and locus-specific sequences of a particular gene (Tanke et 
al., 2005, Bishop 2010). The presence or absence of the disease is assessed based 
on the fluorescent reporter molecule attached to the complementary nucleic acid 
in the tissue section.  
 
In breast cancer patients, this technique can distinguish between malignant and 
benign pigment lesions (Nijhawan et al., 2012). FISH has been approved by the 
FDA to evaluate the gene expression of HER-2. This is achieved based on scoring 
systems set by the FDA and American Society Clinical Oncology/College of 
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American Pathologists (ASCO/CAP). HER-2 gene expression in breast cancer 
patients is confirmed by comparing the gene copy number or the ratio between 
gene and the centomeric region of chromosome 17 (CEP17). Patients with HER-2 
copy number > 4 or HER-2/CEP 17 > 2 are considered to have breast cancer. If 
the ratio between HER-2/CEP17 is < 1.8 the result is negative, whereas the score 
of 1.8 to 2.2 suggest a borderline case (Brunelli et al., 2008, Sapino et al., 2013). 
In primary breast cancer tissue, FISH can also be used to evaluate the expression 
of the estrogen receptor (ER) and the progesterone receptor (PR) (Ma et al., 
2013). 
 
The fluorescent reporter molecules used in these FISH is usually an organic 
fluorophores such as texas red, fluorescein, etc. Herein, also lie the limitations of 
FISH in that organic fluorophores are sensitive to photobleaching and limits 
multiplexing possibilities. Photo-instability of organic fluorophores causes 
photobleaching, which is the fading of the fluorescent signal over time and can 
negatively affect the FISH result. Organic fluorophores typically also have large 
emission spectra, which limits the application of multiple organic fluorophores to 
detect multiple targets/biomarkers, since the potential for spectral overlap is high 
for organic fluorophores. 
 
1.2.4.2.2 Immunohistochemistry (IHC) 
Immunohistochemistry (IHC) has an important role in the medical field, 
especially in pathology for the diagnosis of diseases (Liu et al., 2011). IHC is a 
standard technique used to detect the expression of proteins using an antibody that 
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binds to specific molecules present in the diseased cells (Mahmoud et al., 2011). 
IHC is based on the same principle as FISH; however, it is used to determine 
protein expression instead of gene expression as is the case in FISH. Monoclonal 
and polyclonal antibodies, which targets specific antigens/biomarkers within 
cancerous breast tissue, has been identified (Alam et al., 2013), and are used to 
determine the protein expression in formalin-fixed, paraffin-embedded (FFPE) 
tissue samples (Byers et al., 2007).  
 
IHC is commonly used to evaluate the HER-2 status in breast cancer patients 
(Garrison et al., 2013). The FDA has approved IHC for the assessment of HER-2 
protein expression in breast cancer patients, based on the scoring system 
established by the FDA and ASCO/CAP. The results are based on the ratio of 
HER-2 copy number to that of CEP 17. A score between 0 and 1+ indicate that 
the patient is negative, a 2+ score is weakly positive and considered and 
considered as borderline case which needs further tests to confirm the disease 
status. A positive result will have a 3+ score (Brunelli et al., 2008, Sapino et al., 
2013). IHC has also been used to analyze the expression of PR and ER in locally 
recurrent and primary tissue of breast cancer patients (Ma et al., 2013).  
 
However, IHC is the preferred technique because smaller amounts of tissue is 
required to carry out the test; frozen or fixed tumour tissue samples may be used, 
the technique is widely available, and the assessment is based on the use of light 
or fluorescence microscopy. Detection of the antigen can either be done using 
chromogenic and fluorescence methods. Chromogenic reporters yield an intensely 
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colored product that can be analyzed with a light microscope. Fluorescence 
detection methods make use of fluorescent tags such as texas red, fluorescein, etc. 
Consequently, IHC suffers from similar drawbacks as FISH. 
 
1.2.4.2.3 Quantitative Real Time Polymerase Chain Reaction (qRT-PCR) 
Reverse transcriptase assays have become the most commonly used method for 
characterising gene expression patterns in different sample populations. It is a 
technique that collects and generates data, in real time, with progressive PCR 
cycles (Derveaux et al., 2010). It provides quantitative information as each 
amplicon is doubled by emitting a fluorescent signal, thus combining 
amplification and detection in a single step (Wong et al., 2005, Guénin et al., 
2009). It has become the preferred method due to its high sensitivity, good 
reproducibility and wide dynamic range (Derveaux et al., 2010). The reliability of 
qRT-PCR lies in its sensitivity and ability to detect a single copy of a specific 
transcript. However, some limitations associated with this technique include non-
specific amplification, variations in amplification efficiencies and hetero-duplex 
formation (Pfaffl 2001). Successful qRT-PCR amplification relies on a number of 
factors, termed indicators of a good qRT-PCR. These include the integrity of 
RNA, cDNA and the absence of DNase (Fleige et al., 2006). These steps are 
crucial as it is most likely to introduce variations in the sample due to the presence 
of salts, phenol and other inhibitors that may be carried over from RNA extraction 
(Pfaffl 2001). However, there are many ways to circumvent such variations, if 
encountered. Amongst these are: the type of fluorescent probe used for detection 
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of the DNA as well as the quantification strategy which is very crucial since it 
determines the type of output desired for a particular experiment.  
 
A PCR reaction can be categorized by four major phases. Initially there is linear 
and the early exponential phase. This is followed by the exponential phase (log-
linear) and the plateau phase as shown in Figure 1.3. The most important phases 
in quantification are the early exponential and log-linear phases as this is where 
the actual copy number and the amplification efficiency for a particular transcript 
is calculated from. Data gathered from these phases are important for calculating 
background signal and amplification efficiency. Rn is the intensity of the 
fluorescent emission of the reporter dye divided by the intensity of fluorescent 
emission of the passive dye (a reference dye incorporated into the PCR master 
mix to control for differences in master mix volume). ∆Rn is calculated as the 
difference in Rn values of a sample and either no template control or background, 
and thus represents the magnitude of signal generated during PCR. (Wong et al., 
2005).  
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Figure 1. 3: Phases of the PCR amplification curve. The PCR amplification curve charts the 
accumulation of fluorescent emission at each reaction cycle. The curve can be broken into four 
different phases: the linear ground, early exponential, log-linear, and plateau phases. This graph 
was generated with ABI Prism SDS version 1.9 software (Applied Biosystems). (Wong et al., 
2005).  
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The linear ground phase represents the initial phase of the reaction and accounts 
for very little or no fluorescence other than that ascribed to background 
fluorescence, whereas the early exponential phase accounts for fluorescence 
above that of the background fluorescence. At this stage, the amplicon is 
quantified at each cycle since this is the point of the cycle in which detection 
occurs and is referred to as the crossing point (Cp). The value obtained at the Cp, 
represents the starting copy number of the template and is the value used to 
calculate the output. During the log linear phase, the reaction reaches its optimal 
amplification with each product being doubled in each PCR cycle (Wong et al., 
2005). Linearity can be detected at this point, and the slope can be used to 
calculate the efficiency of the reaction with a slope of 3.32 equating to 100 % 
efficiency. The steeper the slope the lower the efficiency and that could be due to 
factors like handling errors or inferior cDNA (Pfaffl 2001).  
 
The last phase of the PCR is where the PCR components are starting to get 
depleted and this affects the amplification of the PCR product. Consequently the 
amplification plateau as a result of a decrease in PCR efficiency as the product is 
not doubled at every subsequent cycle (Pfaffl 2001). This phase is not used for 
quantification purposes as the target input is depleted. 
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1.2.4.2.3.1 Quantitation strategies in q-Real-Time-PCR 
1.2.4.2.3.2 Absolute quantification 
Absolute quantification essentially relies on known standard housekeeping genes 
to generate a standard curve of known concentration by using a serial dilution of 
the input target DNA. The aim of using a standard curve is to generate a linear 
relationship between the Cp and initial amounts of template, whether it is RNA or 
cDNA. This method permits the accurate quantification of unknown 
concentrations of template by extrapolation based on the Cp values. The main 
advantage of a standard curve is that it generates highly reproducible and stable 
data, and allows for the accurate calculation of PCR efficiency for each template 
reaction. However, this approach is laborious and is highly reliable on whether 
good laboratory practices were employed during experimentation (Pfaffl 2001, 
Schmittgen et al., 2008). 
 
1.2.4.2.3.3 Relative Quantification 
The relative quantitation strategy, measures changes in gene expression based on 
either an external standard or a reference sample, known as a calibrator (Wong et 
al., 2005).  
 
This approach takes into consideration changes in mRNA levels across multiple 
samples and then quantifies their expression levels by the comparing it to the 
expression levels of an internal control usually in a control sample. The 
expression levels are usually expressed in terms of a fold increase or decrease 
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relative to the expression of the internal in the control sample (Pfaffl 2004, 
Dhanasekaran et al., 2010). 
 
Comparison to absolute quantification the approach of relative quantification does 
not require standards with known concentrations and the reference can be any 
transcript (Pfaffl 2001). Currently there are numerous models available to 
calculate the gene expression ratios based on relative quantitation, which include 
the comparative Ct (threshold cycle) method, the Livack method, the Pfaffl 
method and several others (Wong et al., 2005). 
 
The comparative Ct method can be highly inaccurate as it assumes an equal PCR 
amplification for all template samples, and most of the time this is not the case. 
However, this approach is currently used extensively in custom designed and pre-
packed assays plates for pathway analysis and diagnostics research. Although this 
is now an accepted approach in gene transcript expression analysis, it is still not 
the most accurate approach to use. For the purpose of this study, only one method 
will be elaborated on based on a relative quantification approach using standard 
curves. 
 
1.2.4.2.3.4 Pfaffl Method 
The Pfaffl model is the model of choice in most research environments. This 
model combines gene quantification and normalisation into a single calculation. 
The most crucial aspect of this model is that uses the amplification efficiencies of 
both the target and reference genes to correct for the differences in amplification 
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efficiencies between the two assays in both the control and sample assays 
performed. The Pfaffl method employs an excel-based software, known as 
REST®, which automates the data analysis. There is an in-build pairwise Fixed 
Reallocation Randomisation test to determine whether results is significant and is 
indicates whether the reference gene is suitable for normalisation (Wong et al., 
2005). Expression ratios are calculated based on imported Cp from the 
experiments performed and expresses the target gene ratio differences between the 
control and test sample and generates a plot of the ratios for all samples tested 
(Pfaffl 2001).  
 
1.2.4.3 Nanotechnology-based solutions for the diagnosis of cancer 
1.2.4.3.1The use of quantum dots as fluorescent tags in molecular probes  
Quantum dots (Qdot) are nanometre-sized clusters that are composed of a few 
hundred to several thousands of atoms, usually from groups II-VI, III-V and IV-
VI (Rosenthal et al., 2011). Qdot are often synthesized within a size range of 2 to 
10 nm in diameter (Peng et al., 2010). They have unique optical and electronic 
properties such as size-tuneable emission, excellent signal brightness and 
resistance to photobleaching; not exhibited by their organic fluorophore 
counterparts (Xing et al., 2007, Zhang et al., 2008). As a result Qdot can address 
some of the limitations of organic fluorophores in FISH and IHC. Furthermore, 
Qdot have several advantages in fluorescence imaging applications, such as a 
broad absorption spectrum and a narrow emission spectrum (Figure 1.4 A and B) 
(Tabatabaei-Panah et al., 2013). The broad absorption spectra of Qdot allows for a 
wider range of excitation wavelengths (Jamieson et al., 2007) compared to 
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organic fluorophores. The narrow emission spectra can allow for greater 
multiplexing possibilities (Pathak et al., 2006). The implication for diagnostic 
techniques such as FISH and IHC is that the application of Qdot can facilitate the 
detection of multiple biomarkers simultaneously. This can significantly reduce the 
cost and time of diagnosis.  
 
 
 
 
 
Figure 1. 4: Excitation and emission profiles between Qdot (A) and organic fluorophore (B). The 
absorption bands of Qdot extend from the gamma rays region and into the UV region; this width 
absorption band is related to the size of the Qdot, which gave flexibility to multiphoton 
microscopy. Whereas absorption bands of the organic fluorophore have a very narrow range as 
shown in figure 1.3 (B). (Fontes et al., 2012) 
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Qdots have huge potential in cancer diagnostics and imaging. The use of Qdots 
for fluorescent imaging has unique possibilities for cancer imaging at the 
molecular level (Fang et al., 2012, Alam et al., 2013). The application of Qdots as 
imaging agents has already been explored in cancer research by conjugating the 
Qdot to targeting biomolecules such as antibodies and peptides (Zhang et al., 
2008). Another study reported that multicolour Qdots have been used together 
with breast cancer biomarkers such as HER-2 to detect the expression of this gene 
in tissues using Qdot/antibody profiling (Peng et al., 2010, Tabatabaei-Panah et 
al., 2013). The use of Qdots as imaging agents offers much lower detection limits 
with higher accuracy in comparison to traditional diagnostic techniques (Fang et 
al., 2012). 
 
Another application of Qdots is in the development of molecular beacons. 
Molecular beacons have been used in diagnostics assays to test for various 
infections in clinical samples (Tyagi et al., 2012). Molecular beacons have also 
been applied in qRT-PCR assays for the detection of HIV, HBV and HCV 
(Tsourkas et al., 2003, Kim et al., 2008). Molecular beacons are molecular probes 
that target specific nucleotide sequence in the cells. Tyagi and Kramer developed 
molecular beacon technology in 1996 (Tyagi et al., 1996). The use of Qdots in 
molecular beacons will be discussed in more detail in Chapter 4. 
 
 
 
 
 
 
 
 
 32 
1.3 Biomarkers 
Biomarkers play a very important role in the medical diagnostics field since these 
biomolecules are capable of discriminating between physiological and 
pathological conditions. These molecules are the result of altered biological 
processes due to the presence of a disease or due to the effect of a drug treatment. 
In the diagnosis and prognosis of a disease state, they are characteristic of a 
substance that can be objectively evaluated and measured as an indicator of a 
particular biological condition, disease response to medication, therapeutic 
outcome or disease progression and may be used to explore the disease 
mechanism (Strimbu et al., 2010). Therefore, biomarkers can improve the quality 
of health through the early diagnosis and the monitoring of diseases following 
treatment. The sources of biomarkers can include tissues, cells and biological 
fluids (Nie et al., 2007, Strimbu et al., 2010). 
 
The levels of cancer biomarkers vary with progression of the disease and this can 
give insight into various aspects of the disease, such as an individual’s risk of 
developing cancer, the presence of cancer, the molecular mechanisms of cancer, 
the response of the disease to a particular treatment and the recurrence of the 
disease (Figure 1.5). In cancer, biomarkers can be classified as diagnostic, 
prognostic or predictive. Examples of such biomarkers are listed in Table 1.1. 
Diagnostic biomarkers play an important role in screening for individuals who 
have developed the disease or are susceptible to the disease at a later stage i.e. it 
can assess the risk of a patient to develop the disease. These biomarkers can be 
useful in prevention, early detection, intervention and eradication of the disease 
 
 
 
 
 33 
and therefore reduce cancer mortality (Tainsky 2009). Prognostic biomarkers can 
distinguish different stages of the disease, predict clinical outcome and determine 
the course of therapy that must be applied to a particular patient after primary 
treatment (Riley et al., 2009). Examples of prognostic biomarkers in breast cancer 
include BRCA1, HER-2/neu, estrogen receptor (ER) and progesterone receptor 
(PR), which are already used in the medical field (Gerhardus et al., 2007, Mehta 
et al., 2012, Sapino et al., 2013).  
 
 
 
 
 
 
 
 
 
Figure 1. 5: The relevance of cancer biomarkers at different stages of cancer progression (Tainsky 
2009)  
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Predictive biomarkers are used to determine relapse or the recurrence of the 
disease after the patient had undergone treatment (e.g. surgical removal of the 
tumours). A good example of a predictive biomarker for breast cancer is HER-2, 
which has been used to predict sensitivity to Herceptin treatment (Mehta et al., 
2010). The FDA approved this biomarker for use in the diagnosis of breast cancer. 
Several commercial diagnostic tests, which include HercepTest
TM
, Pathway, 
Insite, PathVysion and SPOT-Light HER-2 CISH are available for this biomarker. 
These diagnostic tests most often use molecular diagnostic techniques such as 
IHC, FISH and qRT-PCR (van de Vijver et al., 2007). These methods require a 
biopsy sample from the patient, which means that the diagnostic test is an invasive 
procedure, which can be very uncomfortable to the patient. Other disadvantages of 
biopsy samples include sampling error, which could lead to a false negative result, 
increasing the risk of complications such as hematoma and a more serious aspect 
is the possibility that the tumour cells may migrate into adjacent tissues following 
the procedure (Loughran et al., 2010, Nassar 2011). Even if fine-needle aspiration 
biopsy is used there is still other limitations such as the high cost, the need for 
highly trained medical personnel for the preparation and analysis of the sample 
(Nassar 2011). 
 
Diagnostic tests that are based on the detection of serum biomarkers do not 
require a biopsy sample, since the diagnosis can be done from a blood sample and 
less invasive diagnostic procedures such as ELISA can be used. Serum 
biomarkers are also suitable for application in POC diagnostic devices. Several 
molecular and blood-based assays for different types of serum cancer biomarkers 
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are available. Examples of such biomarkers are listed in Table 1.1 and includes 
prostate-specific antigen (PSA), which was approved by the FDA for use in the 
clinical diagnosis of prostate cancer (Uhl et al., 1997, Chatterjee et al., 2005). 
Bladder tumour antigen (BTA) and nuclear matrix protein-22 (NMP22) are 
amongst the other biomarkers approved by FDA for the screening of bladder 
cancer in urine samples (Mungan et al., 2000, Chatterjee et al., 2005). Human 
epididymis protein 4 (HE4) has been approved by the FDA for monitoring the 
recurrence or progression of ovarian cancer, while Cancer Antigen 125 (CA125) 
has been approved for the monitoring for ovarian cancer in serum (Molina et al., 
2011, Diamandis 2012). To date very few serum biomarkers that are specific for 
breast cancer are known and there is therefore a need to identify additional 
biomarkers for breast cancer. 
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Table 1. 1: A list of known breast cancer biomarkers. 
Gene  Source Sample  Biomarker 
type 
Test  Genetic alteration FDA-cleared test Reference 
ER Breast  Serum  Prognostic and 
predictive  
IHC  Elevated expression ER/PR pharmDx (Majewski et al., 2011) 
PR Breast  Serum Prognostic and 
predictive 
IHC Elevated expression ER/PR pharmDx (Majewski et al., 2011) 
CA15-3  Breast  Serum  Monitoring  -   (Gion et al., 1999, Bast et al., 
2001) 
CA27-29 Breast  Serum  Monitoring    (Gion et al., 1999, Bast et al., 
2001) 
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1.3.1 Methods used to identify biomarkers  
1.3.1.1 Transcriptomics 
Changes in the expression patterns of genes can lead to the development of 
diseases. Various genetic diseases have been identified and can be passed on from 
one generation to the next. Hence, genetic profiling can be used in medical 
research for the identification of genetic markers that can be used to screen for the 
presence of certain diseases, including cancer (Davis et al., 2006, Tainsky 2009). 
This was made possible through genomic technologies such as DNA sequencing, 
DNA microarrays, Serial Analysis of Gene Expression (SAGE), quantitative real-
time PCR (qRT-PCR) and RNA-Sequence (Kawasaki 2006, Schroeder et al., 
2006). 
 
Genomics is a study of an organism’s entire gene complement including the gene 
structure, gene function and control of gene expression. Genomics also entails the 
study of gene networks with the aim of understanding how genes interact with 
each other and with the environment. The sequencing of the human genome has 
demonstrated that it is possible to identify genetic variations responsible for 
diseases and identify individuals that are at risk of developing genetic diseases. 
Understanding the human genome, gene functions and genetic interactions has 
opened avenues in molecular biology for the development of diagnostic and 
therapeutic strategies in the fight against human diseases, more specifically cancer 
(Venter et al., 2001). 
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The development of cancer is characterised by genetic mutations. These genetic 
mutations can be used as genetic or molecular markers for cancer. These genes 
encode proteins that are involved in the regulation of cellular functions (cell 
growth, division and death). Irreversible changes in these gene sequences can 
cause mutations that promote the uncontrolled growth of cells leading to 
development of cancer (Greenman et al., 2007). These mutations can be 
associated with the key identifiable features of cancer cells. 
 
Independent breast cancer studies have identified some mutated genes responsible 
for its development such as breast cancer 1 (BRCA1) and breast cancer 2 
(BRCA2) (Atchley et al., 2008). These molecular markers are currently used for 
diagnostic and therapeutic intervention in breast cancer patients, and have proved 
their potential to help combat cancer (Mayeux 2004).  
 
DNA microarray is one of the most commonly used high throughput techniques to 
study the genome wide gene expression profiles in cells or tissue. In this 
technique, small amounts of DNA or RNA are extracted from cells or tissues to 
determine the copy number of genes/mRNA or DNA region of interest. It has 
enabled researchers to query the mRNA expression levels of thousands of genes 
in an organism simultaneously (Karakach et al., 2010, Pulverer et al., 2012) DNA 
microarrays are collections of microscopic spots created by robotic machines and 
arranged in a grid-like format on a solid support such as a glass slide. Each of 
these microscopic spots represents the cDNA derived from the mRNA of known 
genes. The cDNA’s of several thousand genes can be spotted on a single slide. 
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The process of performing DNA microarray analysis involves a number of steps 
starting with the design of the experiment, the extraction of nucleic acids (usually 
mRNA) from the control (e.g. healthy cells or tissue) and experimental (e.g. beast 
cancer cells or tissue) samples, the transcription of the extracted mRNA into 
cDNA molecules that are differentially labelled (e.g. the controlled sample is 
labelled with Cy5 and experimental samples is labelled with Cy3) with 
fluorescent labels, hybridization of labelled cDNA molecules with the cDNA 
immobilized on the glass slides, scanning of the micro-array, image processing, 
normalization, ratio calculation, statistical analysis, and ending with the extraction 
of information and generation of knowledge from the results (Karakach et al., 
2010). The analysis of the fluorescence signal (intensity and wavelength) of the 
spots on the slide can be used to assess the relative expression levels of thousands 
of genes simultaneously.  
 
The transcriptomic signatures of cancers have been used as prognostic diagnostic 
tools to predict the clinical outcome for breast cancer patients (Wirapati et al. 
2008). MammaPrint®, Oncotype DX™, MapQuant Dx™ and Mammostrat® are 
examples of such diagnostic tests that are currently licensed for commercial use 
(Arpino et al., 2013). Molecular technologies such as qRT-PCR and IHC form the 
bases of the diagnostic tests. 
 
1.3.1.2 Proteomics 
Proteomics refers to the study an entire proteome and protein expression profile in 
a given setting in the given cell type or tissue using high throughput technologies 
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such as HPLC and mass spectrometry (Baak et al., 2005). The objective is to 
identify sets of proteins that are differentially expressed between a normal and 
pathological/disease state (Baak et al., 2005), and thereby potentially creating an 
unique profile or fingerprint for a particular disease, for example breast cancer. 
Quantitative proteomics has been explored, especially in cancer research, to 
determine the changes and pathophysiology of this disease. For instance, in breast 
cancer, useful biomarkers for breast cancer diagnosis have been identified through 
proteomic studies (Liu et al., 2013). Proteomic techniques are sensitive enough to 
detect changes that occur during the development of the disease and also the type 
of modifications induced by the disease state (Liu et al., 2013). Proteomic 
technologies can also provide information on how the protein interacts during the 
development of a disease. Thus, the disease mechanisms and strategies on how to 
prevent, treat and diagnose may be established through proteomics (Baskın et al., 
2010, Wasinger et al., 2013). 
 
1.3.1.2.1 Proteomics technologies 
Proteomics encompasses several technologies have been used for many years as 
for sample analysis tools in chemistry. This includes technologies such as Liquid 
Chromatography Mass Spectrometry (LC-MS), Matrix-assisted Laser Desorption 
Ionization coupled to a Time-of-flight Mass Spectrometer (MALDI-TOF/MS), 
Gas Chromatograph Mass Spectrometry (GC/MS) and Isotope Ration Mass 
Spectrometry (IR/MS) (Nair et al., 2004). Gas Chromatograph Mass 
Spectrometry (GC/MS) and Isotope Ration Mass Spectrometry (IR/MS) (Nair et 
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al., 2004). These technologies are now used to characterise protein samples in an 
effort to identify protein biomarkers for diseases (Nair et al., 2004).  
 
New clinical proteomics technologies such as LC-MS/MS has proved to be useful 
in identifying potential biomarkers from variety of samples including cells, tissues 
and body fluids (Brase et al., 2010). LC-MS/MS is an analytical technique used to 
determine the molecular mass with different sizes, and can be used to characterize 
complex mixtures ranging from proteins, carbohydrates, DNA, drugs, and 
biomolecules associated with disease development and progression and has a very 
high sensitivity of detective (Lee et al., 2010, Grebe et al., 2011). Unlike 
immunoassays, LC-MS/MS can be used to analyze low molecular weight samples 
and samples that is only available in low concentrations even in small amount of 
samples (Kang 2012). 
 
LC-MS/MS has become a very valuable tool for analysis in the medical, clinical 
laboratory field and pharmaceutical analysis (Kang 2012, Haneef et al., 2013), 
pertaining to drug metabolism and toxicology in the body, by following the 
pathways of metabolism of any drug through the identification of circulatory and 
excretory metabolites. During the last 10 to15 years, LC-MS/MS has become the 
instrument of choice in clinical laboratories for the analysis of target peptides and 
proteins. 
 
One of the advantages of using LC-MS/MS in the clinical environment is the 
characterization of thousands of proteins in parallel in clinical samples, and it also 
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enables the study of complex mixtures of peptides, carbohydrate and proteins 
which are unique to relevant disease process (Grebe et al., 2011, Haneef et al., 
2013).  
 
1.3.1.2.2 Stable Isotope Labelling with Amino Acids in Cell Culture (SILAC) 
SILAC involves the in vitro labelling of cellular proteins in cells to allow for the 
comparative analysis of proteomes. Healthy and diseased cells are cultured in the 
same conditions, except that the two populations are grown in media 
supplemented with either “light or “heavy” amino acids. During cell division the 
isotope labelled amino acids replaces the natural amino acids. The process takes 
6-8 doubling times to ascertain 100 % labelling (Ong et al., 2002, Munday et al., 
2012). Lysine and arginine are usually preferred because trypsin would cleave the 
polypeptides at the carboxyl terminal of arginine and lysine residues (Ong et al. 
2003, Munday et al., 2012). The labelled amino acids are similar to the natural 
ones in all respects and therefore the cell growth, cell morphology and biological 
activity of the cells are unaffected. Although chemically similar, the amino acids 
are isotopically different and induce a mass shift that can be distinguished through 
MS (Ong et al., 2002, Ong et al., 2003). The peptides generated by MS can be 
easily correlated to their respective proteins of origin through Bioinformatics 
tools, the ratio of their relative intensity can be used to quantify protein expression 
between normal and disease states (Liang et al., 2006). Initially designed for cell 
culture labelling, SILAC has been used successful to study protein expression in 
brain tissue (Ishihama et al., 2005), the secretome of primary tissues (Grønborg et 
al., 2006) and changes in skin tissues (Zanivan et al., 2013). 
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SILAC has been used successfully to study the proteome of several cell lines for 
the purpose of identifying disease biomarkers and understanding of systems 
biology. For example, the study by Everley et al. (2004) investigated the changes 
in the microsomal proteome of prostate cancer cell lines with varying metastatic 
potential with the aim of understanding the progression of prostate cancer. The 
authors compared the protein expression levels of more than 440 specific proteins 
from the microsomal fraction of prostate cell lines. Their data showed that 60 
proteins were upregulated by a factor greater than 3-fold and 22 proteins were 
down-regulated in the metastatic prostate cell line. Their study suggested that 
SILAC proved to be a useful tool to study the progression of cancer in different 
cancer cell lines. Another study used SILAC to identify and quantify the 
differential expression of proteins between neoplastic and non-cancerous gastric 
cell lines (Marimuthu et al., 2013). In this study 2205 proteins were identified 
from the secretomes of the cell lines. Two-hundred-and-sixty-three (263) proteins 
were overexpressed (greater than 4-fold) in the neoplastic cell line as compared 
the non-cancerous cell line. This study led to the identification of a number of 
potential novel biomarkers for gastric cancer. It is therefore clear that SILAC in 
combination with proteomics is a promising method for the identification of novel 
biomarkers in cancer and could also be used for the quantification of these newly 
identified biomarkers in the diagnosis and prognosis of a variety of cancers. 
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1.3.1.2.3 Mass spectrometry  
Mass spectrometry (MS) is a standard platform employed in the identification of 
proteins isolated from biological samples (Hanash et al., 2008). MS is an 
analytical technique that is used to sequence and identify proteins. The protein 
sample, upon introduction into the MS, is ionized; the resulting mass-to-charge 
ratio of the generated ions is then used to identify the protein molecule (Aebersold 
et al., 2003). Various MS instruments are available and are classified as scanning, 
ion-bean or trapping MS (Yates et al., 2009). The most commonly used MS 
methods include Fourier transform ion cyclotron (FT-MS), ion trap, guadrupole 
and Time of flight (TOF). The preferred methods, in protein biochemistry 
analysis, are matrix-assisted laser desorption/ionization-time of flight (MALDI–
TOF), surface-enhanced laser desorption/ionization-time of flight (SELDI-TOF) 
and liquid chromatography-tandem mass spectrometry (LC-MS/MS) (Aebersold 
et al., 2003, Baskın et al., 2010).  
 
The application of MS to analyze proteins led to the development of a variety of 
emerging proteomics methods for the analysis of clinical samples such as tissues, 
serum and plasma (Schaub et al., 2009). LC-MS/MS is a technique used to 
identify and separate proteins and peptides from complex sample mixtures to 
allow for analysis of individual fractions (Hanash et al., 2008). In terms of protein 
quantification, isotope labelling is currently a powerful strategy. It provides 
accurate measurements of the gene expression and protein-coding and is also 
widely used to analyse small-molecules and identify biomarkers for particular 
diseases (Ciccimaro et al., 2010, Soufi et al., 2010). 
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1.3.1.3 Limitations of proteomics 
Sample preparation is the first and most crucial step when using mass 
spectrometry-based proteomics experiments. Sample preparation refers to all the 
stages that take place before sodium dodecyl sulphate-polyacrylamide gel 
electrophoresis (SDS-PAGE) analysis for gel-based proteomics analysis. Sample 
preparation for proteomic analysis is very delicate and crucial for the best 
outcome. Several factors must be taken into consideration prior to analysis; such 
as the sample type and source and their physicochemical properties since these 
factors will determine the complexity of the sample (Wang et al., 2005). For this 
reason, proteomics is never a single step approach, which will help to determine 
the preparation steps required. The presence of high abundant proteins (HAPs) 
within the sample as well as the sample localization, solubility often complicates 
the sample analysis, therefore, additional steps must be included to successfully 
identify these proteins (Bellei et al., 2011).  
 
For complex samples such as blood, the removal of interfering HAPs from the 
sample is recommended. The sample preparation includes cell lysis, to release or 
extract the total protein; protein solubilization, removal of contaminants 
(interfering proteins) and fractionation to reduce the sample complexity and 
improve its resolution (Wang et al., 2005). Fractionation is used for depletion of 
HAPs on the basis of size, charge, hydrophobicity or binding affinity, to enrich 
and improve the detection range of low abundance proteins (LAPs) by increasing 
the protein load. LAPs of clinical significance can be masked by the presence of 
HAPs. They can be hormones, cytokines, growth factors and high molecular 
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weight proteolytic protein fragments. LAPs are essential for normal biological 
processes and some of them may be potentially useful for diagnostic or 
therapeutic purposes (Wang et al., 2005, Millioni et al., 2011, Liu et al., 2013). 
They can be concentrated to detectable levels necessary for analysis to discover 
their relevance, especially in pathological processes. Various sample preparation 
techniques are available and may also be combined to reduce protein convolution 
prior to its analysis (Wang et al., 2005).  
 
1.3.2 Examples of well characterized biomarkers for breast cancer 
1.3.2.1 Breast cancer type 2 Susceptibility protein (BRCA2) 
Breast cancer type 2 susceptibility locus was discovered by Richard Wooster in 
1994 (Wooster et al., 1994). BRCA2 gene codes for breast cancer type 2 
susceptibility protein, which plays an important role in the maintenance of 
genome integrity during Double-Strand Break Repair (DSBR) replication. This 
protein interacts with proteins that are involved in DNA repair such as proteins 
RAD51 Recombinase (RAD51) and Partner And Localizer of BRCA2 (PALB2). 
Failure to repair DNA damage can lead to replication errors that cause mutated 
DNA, which is propagated, and result in cancer (Schlacher et al., 2011). 
 
BRCA2 is also classified as a tumour suppression gene as described in section 1.1 
(Sharan et al., 1997). This gene is involved in DNA repair pathways, such as 
homologous recombination (Stefansson et al., 2009). The expression of BRCA2 
was observed in different cancer tissues such as prostate cancer and ovarian 
cancer (Goodheart et al., 2009, Castro et al., 2012).  
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Kwong et al. (2009) reported that the clinical risk rate of BRCA2 mutation had a 
significantly high level among 226 Chinese women, and the prevalence of triple 
negative breast cancer in women who were carriers of the BRCA2 mutation was 
high when compared to the Caucasian cohort (Kwong et al., 2009). A new 
deleterious mutation of BRCA2 in exon 15 was identified by Pisano et al. As a 
result of this mutation, the BRCA2 gene becomes completely inactive (Pisanò et 
al., 2011). The BRCA2 functions as a gatekeeper of genomic integrity and it has 
critical step in homologous recombination by regulating the DNA repair protein 
RAD51 gene filament formation (Shuen et al., 2011). 
 
Malone et al studied the prevalence of BRCA2 among black and white American 
women (35 to 64 years old) and found within a total of 1628 women diagnosed 
with breast cancer 674 women without breast cancer; the BRCA2 mutation was 
slightly more prevalent in black women (2.6 %) than in white women (2.1 %). 
Also, the BRCA2 mutation in younger (aged 35 to 45) and older women (aged 45 
to 64) was 4 % and 1.5 %, respectively (Malone et al., 2006).  
 
Recently, 360 breast cancer patients (aged 29 – 76 years) were used in a study in 
which the objective was to detect the BRCA2 mutation using a high resolution 
melting (HRM) assay. The BRCA2 mutation was observed in 27 of the 360 
patients (Xu et al., 2012). Kotsopoulos et al conducted a case-control study within 
seven countries, using women (1665 pairs) carrying the BRCA2 mutation. It was 
concluded that no significant association exists between breastfeeding and the risk 
of breast cancer for at least one year (Kotsopoulos et al., 2012). De Bruin et al. 
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(2012) studied the prevalence of the BRCA mutation among Asian and white 
American women. Fifty Asian women and forty-nine white American women 
were included in the study. It was found that the BRCA2 mutation was more 
prevalent among Asian women 29/50 (58 %) than white American women 18/49 
(37 %) (de Bruin et al., 2012).  
 
Lored-Pozos et al. (2009) reported on the gene expression of BRCA2 among 
premenopausal women, aged 22 - 45 years, diagnosed with breast cancer was 
assessed by RT-PCR. It was found that BRCA2 mRNA expression had no 
association with disease severity in young aged breast cancer women (Loredo-
Pozos et al., 2009).  
 
Another study examined the relationship between BRCA2 expression and some 
clinical factors in breast cancer patients. It was found that the BRCA2 expression 
in patients younger than 50 years of age (53.3 %) was slightly lower than patients 
older than 50 years of age (59.5 %). Based on histological grade, positive BRCA2 
expression marked 24/47 (51.1 %) and 14/20 (70 %) in grade I-II and grade III 
breast tumours, respectively. However, it’s expression in axillary lymph node 
metastasis was 28 out of 50 (56 %) (Li et al., 2011).  
 
1.3.2.2 Human Epidermal Growth Factor Receptor 2 (HER-2/neu) 
Human epidermal growth factor receptor 2 (HER-2), also known as C-erbB-2, is a 
transmembrane glycoprotein and member of the tyrosine kinase family. HER-2 is 
a proto-oncogene that is located on chromosome 17q21 and encodes for a 185-
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KDa protein (Yoshino et al., 1994, Roşian et al., 2005). HER-2 was discovered in 
1985 (Groudine et al., 1985), and it was approved by the FDA in 1997 as 
diagnostic biomarker for breast cancer using the FISH technique (Ross et al., 
2009). It is over expressed in approximately 25-30 % of breast cancers and its 
expression is particularly high in invasive breast cancer specimens. 
Overexpression of HER-2 has been associated with negative expression of ER 
(Groudine et al., 1985, Lee et al., 2007). HER-2 is also an important biomarker 
target for the treatment of this disease. Patients with high levels of HER-2 
expression are good candidates for treatment with trastuzumab, which is a 
monoclonal antibody-drug conjugate that acts by blocking HER-2 (Radojicic et 
al., 2011).  
 
At present, the only HER-2 targeted therapy approved by the FDA for the 
treatment of metastatic breast cancer (MBC) is the drug, tastuzumab. The HER-2 
protein is an important therapeutic target in breast cancer for several reasons. 
Firstly, HER-2 is known to be overexpressed in 20–25 % of invasive breast 
cancers (Slamon et al., 1987, Slamon et al., 1989, Nahta et al., 2006) and is 
associated with poor prognosis in the disease. HER-2 overexpression is also 
associated with resistance to certain chemo- therapeutic agents and this decreases 
the effectiveness of trastuzumab. The overexpression of this receptor is generally 
due to gene amplification, which can result in up to a 25-fold increase in HER-2 
copy number (Press et al., 2002, Nahta et al., 2006). The normal levels of the 
HER membrane-bound receptor is reported to be 20,000 per cell. HER-2 
overexpression has been defined by immunohistochemistry and is classified as 
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being highest (reported as 3+) when the receptor levels are in the region of 2 
million per cell, or medium (2+) when receptor levels are approximately 500,000 
per cell (Ross et al., 2004). Secondly, the pathogenesis and prognosis of breast 
cancer is also strongly correlated with elevated HER-2 levels) (Slamon et al., 
1987, Slamon et al., 1989, Nahta et al., 2006). Thirdly, in human cancer cells the 
level of gene amplification is much higher than in normal adult cells and thus, 
targeting the HER-2 protein with HER-2- targeted drugs could reduce the 
pathogenicity caused by HER-2 overexpression. Lastly, HER-2 protein levels are 
known to be relatively homogeneous among HER-2-overexpressing tumour cells 
(Eccles 2001).  
 
HER-2 expression is an important predictive and prognostic factor in breast 
cancer. A study done in North Pakistan on a total of 1226 patients diagnosed with 
IDC found that 478 of these patients were positive for HER-2 expression (Faheem 
et al., 2012). Kinsella et al. (2012) compared the IHC profile generated for HER-2 
in pre- and post- neoadjuvant chemotherapy among 37 females diagnosed with 
primary breast carcinoma and found that 32 % of the patients were positive for 
HER-2 prior to the neoadjuvant chemotherapy. This dropped to 22 % after the 
treatment (Kinsella et al., 2012).  
 
In another study, the expression of HER-2 was studied in 1134 female subjects (≥ 
18 years old) diagnosed with invasive breast cancer. It was found that 18 % of the 
cases were HER-2 positive (Onitilo et al., 2009). Using IHC, Yanagawa et al. 
(2012) showed that 30 out of 363 primary invasive breast cancer patients (aged 30 
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to 87 years) were positive for HER-2; none of which had a family history of breast 
cancer (Yanagawa et al., 2012). The presence of HER-2 in CTCs in breast cancer 
patients was reported by Fehm et al. (2009); a study in which 431 blood samples 
were analysed. The detection rate, for HER-2, was 38 % (22/58 patients) in CTCs 
(Fehm et al., 2009). The expression of HER-2 was investigated in human ductal 
breast carcinoma patients, a total of 69 samples were examined by IHC. A product 
of IHC as an indicator of HER-2 expression was present on the cell surface of 
cancer cells. Staining for 21.74 % of the cell field was observed, while 28.98 %, 
26.01 %, 23.19 % and 21.74 % exhibited strong, moderate and weak staining, 
respectively (Sopel et al., 2011). Subik et al. (2010) analysed the level of HER-2 
in 17 common breast cancer cell lines using an IHC assay and HER-2 was shown 
to overexpress in 4 cell lines only (SKBR-3, MDA-MD-435, AU 565 and BT-
474) (Subik et al., 2010).  
 
The expression of HER-2 was evaluated using IHC. It was observed as positive 
(3+), weakly positive (2+), negative (1+) and negative (0), the expression was 3+ 
in 14 % (21 patients), 2+ in 10.7 % (16 patients) and 0/1 in 75.3 % (113 patients), 
but with FISH, the expression was detected in 18 specimens (all positive with 3+). 
(Schoppmann et al., 2010). IHC and FISH techniques were used to detect HER-2 
expression in invasive breast cancer patients (n=1984). The expression of HER-2 
was found to be up-regulated in 75.4 of the cases (Caldarella et al., 2011). 
Another study examined tissues from 518 invasive breast cancer patients and the 
results revealed that 155 patients scored positive (Moelans et al., 2009). The 
amplification of HER-2 in breast cancer was evaluated with using IHC and FISH, 
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30 out of 114 (26 %) breast cancer samples were amplified by FISH, whereas 
about (18 %) were IHC positive (Ellis et al. 2005). Al-Dujaily et al. (2008) 
conducted a study in which he collected 90 specimens of breast cancer tissues, 
including 20 normal tissue samples as a control and 25 benign breast lesions. 
HER-2 expression level was detected in 67.8 % of the cases; and 73.2 % of IDC 
cases and 12.5 % of ILC cases, while the expression was negative in all normal 
and benign breast lesions (AL-Dujaily et al., 2008). Stark et al. carried out a 
study, between 2001 and 2007, using women from African/white American 
origin. A total of 581 African American and 1008 white American women were 
tested for HER-2 expression using the FISH assay. The assay indicated 82.9 % 
and 76 % of white American and African American women, respectively, were 
positive for HER-2 expression; while (75.1 % 332/581) of the African American 
and 76.7 % of the white American women were negative for breast cancer (Stark 
et al., 2010). Recently, Joensuu et al. (2013) reported that the HER-2 gene level 
was evaluated in 72 females with primary breast cancer, of which 21 % of the 
cases were positive (Joensuu et al., 2013). Georgescu et al. (2012) reported on the 
presence of the HER-2 gene in 27.5 % of females with invasive breast carcinoma, 
while 72.5 % of the patients were HER-2 negative (Enache et al., 2012). 
 
Another study evaluated HER-2 status in 90 cases of mammary invasive 
carcinoma. The expression of the HER-2 oncoprotein was assessed as negative in 
65.55 % cases, while positive cases were found to be 54.44 %, 11.11 %, 18,8 % 
and 15.56 % presented score 0, 1+, 2+ and 3+, respectively (Pătrană et al., 2012).  
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1.3.2.3 Fork head  
The fork head is a family of transcription factors, usually characterized by a 100-
amino-acid, monomeric DNA- binding domain (Kaestner et al., 2000). It was 
discovered on the basis of specific DNA binding activity present in liver nuclear 
extracts for a specific promoter region (Friedman et al., 2006). Among this family 
is the Fork head box A1 (FOXA1), also known as hepatocyte nuclear factor 3 
alpha (HNF3a) (Kaufmann et al., 1996, Thorat et al., 2008), and is located on 
chromosome 14q21.1 (Nucera et al., 2009, Robinson et al., 2013).  
 
According to Wolf et al. (2002), the expression of FOXA1 was found in the liver, 
breast, bladder, pancreas, colon, lung and metastasized prostate cancer (Wolf et 
al., 2007, Jain et al., 2011). Wolf et al. (2002) reported that the expression level 
of FOXA1 in IDC is higher (94 %) than in pure DCIS (85 %) and those normal 
tissues adjacent to cancerous breast tissue expressed high levels of FOXA1. 
However normal breast tissues showed low expression and correlated with 
favorable prognostic factors such as tumour grade (Wolf et al., 2007).  
 
Furthermore, FOXA1’s expression was correlated with the luminal breast cancer 
subtype (Thorat et al., 2008). Hadashy et al. (2008) reported on the 
overexpression of FOXA1 in the nuclei of malignant and luminal ductal cells 
(Habashy et al., 2008). Additionally, its expression was associated with tumour 
size (Habashy et al., 2008, Albergaria et al., 2009), however, no association 
between FOXA1 and the patients age in lymph node stage (Habashy et al., 2008). 
Some studies show that the expression level of FOXA1 decreases with an increase 
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in tumour grade, tumour stage (Abe et al., 2012), and nuclear grade (Hisamatsu et 
al., 2012). 
 
Yamaguchi et al. (2008) evaluated FOXA1 mRNA expression in a panel of 35 
human breast cancer cell lines and positively correlated overexpressed FOXA1 
with GATA3 in 63 % of the cell lines. In the same study they examined if any 
correlation occurs between FOXA1 and ERbB2 as a marker of poor prognosis in 
human breast cancer. The results revealed an up-regulation of FOXA1 in all of the 
ErbB2-positive breast cancer cell lines (Yamaguchi et al., 2008). A number of 
studies had suggested that FOXA1 is a significant predictor in breast cancer 
(Albergaria et al., 2009, Mehta et al., 2012), and was associated with good 
prognosis (Thorat et al., 2008). This was confirmed in a study carried out by 
Hisamatsu et al. (2012), in which the overexpression of FOXA1 in ER- and PR-
positive breast cancer patients was recognized as a good prognostic indicator 
(Hisamatsu et al., 2012).  
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1.5 Aims of the study 
The aims of the study were 1) to identify new potential biomarkers for breast 
cancer and 2) to develop molecular beacon technology (using quantum dots as the 
fluorescent signal) for applications in the diagnosis of breast cancer that can 
potentially be used in multiplex diagnostic assays. 
 
1.5.1 The objectives of this study include: 
 To use comparative proteomics analysis to identify membrane proteins 
that is differentially expressed between the human breast cancer cell line 
(MCF-7) and the non-cancerous human breast cell line (MCF-12A).  
 To validate any new biomarkers in MCF-7 and MCF-12A cell lines as 
well as breast cancer patient samples using online bioinformatics tools 
such as GeneHub and molecular techniques such as qRT-PCR and IHC. 
  To develop a molecular beacon probe for the detection of a known breast 
cancer biomarker 
 
1.5.2 Hypothesis  
Gene expression analysis such as DNA microarray has traditionally been used to 
identify disease biomarkers but this technology is prone to limitations. Proteomics 
on the other hand is a far more promising technology for the identification of 
disease biomarkers.   
 
The identification of proteins that are over expressed in beast cancer cells can lead 
to the discovery of new biomarkers for this disease. Membrane proteins that are 
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involved in the pathology of breast cancer are over expressed in breast cancer 
tissues and cell lines derived from breast cancer tissue. Membrane proteins would 
be ideal biomarkers since these proteins are expressed on the surface of cells and 
can therefore facilitate the development of diagnostic methods that are less 
invasive. Proteomics can be used to identify these proteins. 
 
The application of quantum dots as fluorescent signals in diagnostic techniques 
such as FISH, IHC and molecular beacons can lead to the production of 
diagnostic methods that are faster and cheaper, since quantum dots are more 
photostable and can potentially facilitate multiplex detection of several 
biomarkers in the same sample. Multiple genes that encode biomarkers, including 
membrane proteins can be detected using molecular beacon technology where 
quantum dots are used for the fluorescent signal. 
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CHAPTER 2 
 
2.1 Materials and methods  
Table 2. 1: General chemicals and materials suppliers  
Item  Supplier 
0.4 % trypan blue stain Invitrogen 
 1-Ethyl-3-(3-dimethylaminopropyl) 
carbodiimide hydrochloride (EDC) 
Sigma-Aldrich 
1 X Phosphate Buffer Saline PBS, pH 7.2 Invitrogen  
6 X orange DNA loading dye Fermentas 
Acetone Merck 
Acrylamide-Bis (37.5:1), 40 % Serva (GMbH) 
Agarose Lonza 
Amicon Ultra-0.5 centrifugal filters Merck 
Ammonium persulphate (APS) Merck 
Bacteriological agar Merck 
Boric acid Merck 
Bovine serum albumin Roche  
Bromophenol blue  Sigma 
Coomassie Brilliant Blue R250 Sigma 
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Dimethyl sulphoxide (DMSO) Sigma 
Dithiothreitol (DTT) Thermo Scientific 
DNA molecular weight marker ladder 
(100 bp) 
Fermentas 
Ethanol Merck 
Ethylene diamine tetra acetic acid 
(EDTA) 
Merck 
Formalin  Merck  
Gel Red Nucleic acid stain BioTIUM  
Glacial acetic acid Merck 
Glycerol Merck 
Glycine Merck 
Hydrochloric acid Merck 
Isopropanol Merck 
Magnesium Chloride (50 mM) Separation 
Methanol Merck 
N,N,N’,N’-Tetra methylethylene-diamine 
(TEMED) 
Merck 
Oligonucleotides  Integrated DNA technology (IDT) 
PF Syringe Filter 0.8/0.2 m (PALL) life science 
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Polyvinylidene difluoride transfer 
membrane (PVDF) 
BIO-RAD 
Potassium chloride (KCl) Merck  
Protease inhibitor cocktail (complete, 
EDTA-free) 
Roche 
Qdot® 525 ITK™ Carboxyl Quantum 
Dots 
Invitrogen Life technologies 
Sodium dodecyl sulphate (SDS) Merck 
Sodium hydroxide Merck 
Tris (hydroxymethyl) aminoethane  Merck 
Triton X-100 Sigma 
Tween-20 (polyoxyethylene[20] sorbitan) Merck 
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Table 2. 2: Cell culture material and suppliers  
Item Suppliers 
DMEM: F12 Media Lonza 
Fetal Bovine serum (FBS) Biochrom  
Hydrocortisone Sigma-Aldrich 
Insulin Roche 
LONG® EGF human SAFC Biosciences 
Penicillin/Streptomycin (10.000 U/ml) Lonza 
Trypsin (2.5 %) Gibco® 
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Table 2. 3: Biochemical assay kits and suppliers 
Kit Suppliers 
BM Cyclin Kit Roche 
Clarity
TM 
Western ECL Substrate BIO-RAD 
KAPA SYBER
® 
FAST qPCR kit for 
LightCycler
®
480 
KAPABiosystems 
MycoFluor
TM
 Mycoplasma detection kit (M-7006) Life technology 
NucleoSpin® RNA/protein extraction kit  Macherey-nagel GmbH 
Pierce® Cell Surface Protein Isolation Kit  Thermo scientific 
Pierce® SILAC Protein Quantitation Kits  Thermo scientific 
SuperSignal
TM
 West Pico Chemiluminescent 
Substrate 
Bio-Rad 
Transcriptor first strand cDNA synthesis Kit Roche 
 
  
 
 
 
 
 62 
 
Table 2. 4: Stock solutions and Buffers  
Stock solution and Buffer  Composition 
1 X Transfer Buffer  0.049 M Tris –HCl (pH 8.3), 0.38 M glycine 
and 20 % methanol. This solution was stored 
at 4 
°
C.  
1 X Tris EDTA (TE) 10 mM Tris- HCl (pH8.0), 1 mM EDTA  
10 X Tris, Boric acid and EDTA 
(TBE) 
0.9 M Tris, 0.9 M Boric acid and 25 mM 
EDTA, pH 8.3  
1 X Tris, Boric acid and EDTA 
(TBE) 
10 X TBE was diluted 1:10 times  
10 X SDS Electrophoresis 
Buffer 
250 mM Tris-HCl pH 8.3 1.92 M Glycine 
and 10 % SDS. 
12 % Separating gel  
 
40 % Polyacrylamide, 1.5 M Tris–HCl (pH 
8.8), 10 % Ammonium Persulphate, 10 % 
SDS, 0.002 % TEMED 
12 X Separating gel Buffer  1.5 M Tis-HCl, pH 8.8. 
1 X Phosphate Buffer Saline 
PBS  
137 mM NaCl, 2.7 mM KCl, 8 mM Na2HPO4 
and 1.5 mM KH2PO4, pH 7.4. 
1 X Tris-Buffered sodium 
chloride Tween-20-Bovine 
serum albumin 
3 g BSA was diluted in 100 mL 1 X 
TBSTween-20 
1 X Tris-Buffered sodium 5 g fat free milk powder was dissolved in 100 
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chloride Tween-20-Milk mL TBSTween-20  
2 X Sample Buffer 4 % SDS, 25 % glycerol, 10 mM DTT, 100 
mM Tris-HCl pH 6.8, 0.01 bromophenol 
blue. This Buffer was stored at -20 
°
C and 
supplemented with 10 mM (final 
concentration) DTT when used. 
5 % Stacking gel 40 % Polyacrylamide, 1 M Tris (pH 6.8), 10 
% Ammonium Persulphate, 10 % SDS, 0.002 
% TEMED 
Ammonium persulphate  A 10 % Stock solution was prepared in dH2O 
Coomassie staining solution 0.25 % Coomassie Brilliant Blue (R250), 40 
% Methanol, 10 % acetic acid and 50 % 
distilled H2O. 
Destaining solution 10 % methanol, 10 % acetic acid in distilled 
H2O 
Dithiothreitol (DTT)  A 1 M stock solution was prepared in dH2O 
and sterilized by filtration (0.22 μm filter), 
the solution was aliquoted and stored at -20 
°
C . 
Paraformaldehyde (PFA) 
 
4 % (w/v) prepared in half the final volume 
distilled water, which was heated to 60 
°
C, the 
pH was adjusted to 7.4, the solution was 
made up to final volume, filter sterilized, and 
stored at 4 
°
C 
Sodium dodecyl sulphate (SDS) 10 % in distilled water. 
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Table 2. 5: Equipment used 
Instrument Supplier 
ABI StepOnePlus Applied Biosystems 
Axioplan 2 imaging Fluorescence microscope Zeiss 
BASIC 20 pH-Meter Lasec 
BioSepectrum® Imaging system  UVP 
Countess™ Automated cell counter  Invitrogen 
Eppendorf 5417 R microcentrifuge with rotor F45-30-
11 
Eppendorf 
GeneAmp PCR system 2700 Applied Biosystem 
Inverted light Microscope  Nikon TMS-F 
Lieca EC3 Digital camera  Lieca Microsystems 
Ltd. 
NanoDrop ND1000 Thermo Scientific 
POLAR star Omega Microplate reader BMG LABTECH  
TBS/Tween-20 20 mM Tris-HCl pH 7.4, 150 mM NaCl and 
0.1 % Tween-20. This solution was stored at 
4 
°
C. 
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Power Pac Basic HC 300W Bio-Rad 
Qubit®2.0 Fluorometer Invitrogen 
Sorvall TC6 centrifuge H 400 American Instrument 
Exchange, Inc. 
Thermo Fisher Incubator Shaker Thermo Fisher 
Scientific Inc 
Thermomixer comfort 1.5 mL Eppendorf 
Trans-Blot®Turbo
TM
 Transfer System BIO-RAD 
Vortex Mixer Labnet international 
Inc. 
Water Jacked CO2 incubator Forma Scientific 
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Table 2. 6: Cell lines and the media 
Cell line Organism Tissue Media 
MCF-7 Human  Breast carcinoma, 
mammary gland  
DMEM:F12 supplemented with 20 
ng/ml EGF, 5 % FBS, 500 ng/ml 
hydrocortisone and 0.01 mg/ml 
bovine insulin 
MCF12-A  Human  Breast epithelial 
mammary gland 
DMEM:F12 supplemented with 20 
ng/ml EGF, 5 % FBS, 500 ng/ml 
hydrocortisone and 0.01 mg/ml 
bovine insulin  
 
 
 
Table 2. 7: List of the Antibodies  
Antibody  Supplier 
Goat anti-mouse antibody IgG-HRP: Sc-2055 Santa Cruz Biotechnology, Inc. 
Pan-Cadherin antibody (4068) Cell Signalling (Technology) 
Anti GDNF Receptor alpha 1 antibody Biocom-Biotech  
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2.2 Methodology  
2.2.1 General cell culture procedure  
The MCF-12A human mammary gland epithelial cell line has been derived from 
non-cancerous female breast tissue of a 60-year-old Caucasian female (Immortal 
human mammary epithelial cell sublines 1993). This cell line was obtained from 
American Type Culture Collection (ATCC) at passage 59. The MCF-7 human 
mammary gland breast adenocarcinoma was derived from the metastatic cancer 
site of a 69-year-old Caucasian female (A human cell line from a pleural effusion 
derived from a breast carcinoma 1971). This cell line was obtained from ATCC at 
passage 147. Cryovials were obtained from ATTC and stored at -150 
°
C.  
 
The media for both cell lines was prepared as follow DMEM:F12 medium 
containing 2 mM L- glutamine was supplemented with 5 % Fetal Bovine serum 
(FBS), 100 μg/ml penicillin/streptomycin, 0.01 mg/ml insulin, 500 ng/ml 
hydrocortisone and 20 ng/ml epidermal growth factor (EGF).  
 
2.2.2 Thawing of cells  
Cryovials containing the cells were placed in a water bath at 37 
°
C and thawed for 
1-2 min with constant agitation until the visible ice was melted. The cells were 
transferred into 15 mL sterile centrifuge tubes containing 9 mL of pre-warmed 
complete cell culture media. The tubes were centrifuged for 3 min at 1600 rpm in 
a bench top Sorvall TC6 centrifuge H400. The supernatant was discarded and the 
cellpellet was re-suspended in 5 mL of fresh pre-warmed complete media. 
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2.2.3 Culturing of cells  
After thawing (2.2.2) the cells were seeded in 25 cm
2
 cell culture flasks, and 
incubated in an atmosphere of 5 % CO2 at 37 
°
C in a humidified incubator water 
Jacked CO2 incubator. The cells were checked continuously for normal 
morphology, density and absence of bacterial and fungal contaminations using 
inverted light microscope with the 20 X objectives. The images were taken using 
a Lieca EC3 camera (Lieca). The media was changed three times a week until the 
density of the cells was about 80-90 %.  
 
2.2.4 Trypsinization of cells  
When the cell density reached 80-90 %, the media was discarded, the cells were 
washed twice with 5 mL sterile 1 X Phosphate Buffer Saline (PBS). The PBS was 
discarded; 3 mL of a 0.25 % trypsin solution was added to the flask. The flasks 
were returned to the incubator for 1- 5 min until cells were detached. Immediately 
there after 3 mL of pre-warmed medium was added to stop the trypsinization, the 
cells were transferred into a sterile 15 mL tube and centrifuged at 3000 rpm for 5 
min in a Sorvall TC6 centrifuge H 400. The supernatant was discarded and the 
pellet was resuspended in pre-warmed media. The number and viability of the 
cells were evaluated as indicated in section 2.2.7 The cells were either sub-
cultured or prepared for long-term storage at -150 
°
C in cryovials. 
 
2.2.5 Mycoplasma screening of cell culture 
The cells were routinely checked for mycoplasma contamination using 
MycoFluor
TM
 Mycoplasma detection kit A flask of cells was trypsinized as 
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described in 2.2.4, and seeded in 6 well plates. Each well contained a cover glass 
(22 X 22 mm) that was autoclaved prior to placing the cover glass into the well. 
The cells were incubated until about 75 % confluency was reached. The cells were 
incubated in 5 X MycoFluor reagent (prepared in growth media) for 10 min at 
room temperature. The coverslip was placed onto clean microscope. The edges of 
the coverslip were sealed using wax. The slide was examined by using the 
Axioplan 2 imaging-Zeiss, fluorescence microscope. 
 
MB Cyclin (Pleurontilin and tetracycline derivatives) was used to eliminate the 
mycoplasma contamination. The stock solution was made by adding 10 mL of 
sterile dH2O to BM Cyclin 1 (25 mg/ml) and BM Cyclin 2 (12.5 mg/ml), and the 
content was dissolved completely, aliquoted in to a sterile labelled Eppendorf 
tubes and kept at -20 
°
C.  
 
The cells were seeded as explained in sections 2.2.3. The cells were incubated for 
3 days in BM Cyclin1 (10 μg/ml) followed by 4 days incubation in BM Cyclin2 
(5 μg/ml). These steps were repeated twice and then the cells were checked for 
mycoplasma as explained above. 
 
2.2.6 Cryovial preservation of cells  
Once the cells were approximately 80-90 % confluent and free of fungal, bacterial 
or mycoplasma contamination. The cells were trypsinzed with 0.25 % trypsin as 
explained in section 2.2.4. 
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 The cells pellets were resuspended in complete medium containing 10 % 
Dimethyl sulphoxide (DMSO). 
 
The cells were counted and the viability was determined as described in section 
2.2.7. If the viability of the cells were more than 90 %, the cells were considered 
healthy for freezing and storage. Cryovials were labelled appropriately with 
complete information such as date of freezing, cell type, the passage number of 
the cells, the name of the users (initials) and the media for the cell line. For each 
labelled vial, 1ml of the cells (at a concentration of 2-4 x 10
6 
cells per ml) was 
aliquoted into the vials were sealed. The Cryovials were immediately placed at      
-150 
°
C for long-term storage.  
 
2.2.7 Cell counting with the countess Automated Cell Counter  
The number and viability of the cells were determined as per the manufactures 
instructions using the Countess™ Automated cell counter. After trypsinization the 
cell suspension (40-50 μL) was mixed with an equal volume of 0.4 % trypan blue 
stain. The Countess chamber slides were loaded with 10 μL of the sample.  
 
2.3. Stable Isotope Labelling of cells 
Stable Isotope Labelling by Amino Acids in Cell Culture (SILAC) is a technique 
that depends on cellular proteins synthesis to incorporate isotope medium, which 
contain amino acids, such as lysine containing 
13
C6 or arginine. 
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Two different populations of the cell (MCF-7 and MCF-12A) were seeded at 1 X 
10
5
 cells in 75 cm
2
 cell culture flasks as described in section 2.2.3. In two separate 
medium formulations, SILAC was used for comparative, quantitative of proteome 
analysis between MCF-7 and MCF-12A cells based on incorporation of the 
labelled amino acid into newly synthesised proteins. 
 
Pierce® SILAC protein quantitation Kit (Thermo scientific) was used for 
labelling of the cells with specific amino acid, following the manufacture’s 
instructions. The MCF-7 were grown in DMEM:F12 media containing 50 mg/ml 
of 
13
C6 L-Lysine-2HCl heavy label while MCF-12A cells were grown in the 
natural amino acid (L-Arginine-HCl) light. Cells were cultured in the SILAC 
medium for 8 doubling to allow for the incorporation of the amino acids.  
 
2.3.1 Isolation of Plasma membrane proteins  
In order to isolate the membrane protein from MCF7 and MCF-12A cells, 
Pierce® Cell surface protein isolation Kit (Thermo scientific) was used. The 
media was removed and the cells were washed twice with ice-cold 1 X PBS. The 
cell surface proteins were tagged with biotin by adding 10 mL biotin solution 
(EZ-link Sulfo-NHS-SS-Biotin Thermo Scientific) to each flask. The flasks were 
placed at 4 
°
C with orbital shaking for 30 min. The biotin tagging reaction was 
quenched by adding 500 μL quenching solution (Thermo Scientific) to each flask. 
Cells were scraped off, transferred into 50 mL conical tubes and centrifuged at 
500 xg in a bench top Sorvall TC6 centrifuge H400 for 3 min. The supernatant 
was discarded and the pellet was resuspended in 5 mL TBS. The suspension was 
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centrifuged at 500 xg for 3 min and the supernatant was discarded. Lysis Buffer 
(Thermo Scientific) consisting of 500 μL Lysis Buffer and 20 μL Protein inhibitor 
(Thermo Scientific) was added to the pellet. 
 
The cells were lysed by sonication at low power for 5 Sec and incubated for 30 
min on ice. The solubilization was improved by vortexing the tube every 5 min 
for 5 Sec using vortex mixer. The cell lysate was centrifuged at 10 000 xg for 2 
min at 4 
°
C using a bench top centrifuge (Eppendorf 5417 R microcentrifuge with 
rotor F45-30-11). The supernatant (clarified cell lysate) was transferred to a 1.5 
mL sterile tube. For isolation of the biotin tagged proteins, a gel column needed to 
be prepared. The column (Thermo Scientific) was assembled by placing the 
column into a 2 mL collection tube. The column was capped and 500 μL of 
NeutrAvodin Agarose was added and the column was centrifuged at 1000 xg for 1 
min. The flow-through was discarded. The agarose column was washed by adding 
500 μL Wash Buffer to the column and centrifuging it at 1000 xg for 1 min. The 
washing step was repeated twice.  
 
The bottom of the column was tightly closed off and then the cell lysate was 
added to the column. The top of the column was closed off and the column was 
incubated for 60 min at 25 
°
C with end-over-end mixing using a rotator. Both caps 
were removed and the column was centrifuged at 1000 xg for 1 min. The flow-
through was discarded and the bottom cap was replaced. To remove un-bound 
proteins (cytosolic and nuclear proteins) the column was washed three times with 
500 μL Washing Buffer (Wash Buffer contained protease inhibitor). For protein 
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elution, 400 μL of sample Buffer (SDS-PAGE sample Buffer with 50 mM 
Dithiothreitol (DTT) was added to the column and the column was incubated for 
60 min at 25 
°
C with end-over-end mixing using a rotator. The bottom cap of the 
column was removed and the column was placed into a new collection tube. The 
column was centrifuged at 1000 xg for 2 min. The membrane proteins were 
quantified described in section 2.3.1.1 and kept at -20 
°
C for future use.  
 
2.3.1.1 Protein Quantification 
The protein concentrations of the samples were determined using the Qubit® 2.0 
Fluorometer (Invitrogen), according to the manufacture’s instructions. All 
reagents were equilibrated to 25 
°
C before use. The following steps were taken in 
order to measure the concentration of protein using the Qubit™protein assay kit.  
 
A 200 µL Qubit™ Working Solution for each standard and sample was prepared 
in a clear, thin-walled 0.5 mL PCR tube, by diluting the Qubit™ reagent in the 
Qubit Buffer (1:200). The assay tubes were then prepared as shown in table 2.8 
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Table 2. 8: Reagents utilized for protein quantification  
 Standard 1 Standard 2 Standard 3 Sample tubes 
Working solution 190 µL 190 µL 190 µL 190 µL 
Standards 10 µL 10 µL 10 µL - 
Sample - - - 10 µL 
TOTAL volume 200 µL 200 µL 200 µL 200 µL 
 
 
The standards and samples assay tubes were mixed by vortexing, followed by 
incubation for 2 min at 25 
°
C. The protein concentration for each standard was 
quantified and used to generate a calibration curve using the Qubit® 2.0 
Fluorometer. The protein concentration for each sample was then extrapolated 
from the standard curve. 
 
2.3.1.2 One-dimensional Sodium-dodecyl-sulfate-polyacrylamide gel 
electrophoresis (1D SDS-PAGE) 
The concentration of the proteins were determined using Qubit® 2.0 Fluorometer 
(invitrogen) as described in section 2.3.1.1, protein samples were loaded onto gels 
at 100 μg/μL following heating at 95 °C for 10 min. 
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2.3.1.3 Preparation of PAGE  
Proteins were separated by denaturing SDS-PAGE according to the method of 
(Laemmli 1970). Briefly the gels were made from 40 % stock of premix 37.5:1: 
bisacrylamide (Serva GMbH). The separating gel consisted of 12 % acrylamide: 
bisacrylamide (37.5:1), 0.375 M Tris-HCl, (pH 8.8), 0.5 % ammonium 
persulphate, 0.1 % SDS and 0.02 mL (0.198 %) TEMED. The stacking gel 
consisted of 5 % acrylamide: bisacrylamide (37.5:1), 0.125 M Tris-HCl (pH 6.8), 
0.5 % ammonium persulphate, 0.1 % SDS and 0.01 mL (0.198 %) TEMED. The 
gels were prepared in 1 mm Hoeffer dual gel casters, and about 10 mL were 
enough for one gel. The separating gel was poured to about 1 cm below the level 
of the wells of the comb and about 2 mL of isopropanol was overlaid on top of the 
separating gel and the gel was allowed to set. Once set, the distilled water was 
poured off and the gel rinsed with deionized water. Stacking gel (~5 mL) was 
poured on top of the separating gel and a comb was inserted into the stacking gel. 
The gel was allowed to solidify. When the stacking gel was set, the comb was 
removed and the gel was transferred to the Mighty Small apparatus (Hoeffer). 
 
The protein samples were prepared by mixing the samples1:1 (v:v) with 2 X SDS 
Sample Buffer. The samples were boiled for 10 min, centrifuged for 5 min at 10 
000 xg, the samples were loaded into gels and electrophoresis in 1 X SDS 
Electrophoresis Buffer at 100 V (constant voltage) for 15 min. The voltage was 
increased to 120 V (constant voltage) until the bromophenol dye reaches the 
bottom of the gel. One the gels was transferred onto a polyvinylidene fluoride 
(PVDF) membrane while the other gel was stained with Coomasssie stain. 
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2.3.1.4 Staining and Destaining of the gels 
After electrophoresis, the gel was removed from the casing. And incubated in 
Coomassie Stain Solution for 1 hour on an orbital shaker. The gel was destained 
over night in Destaining Solution on an orbital shaker at 25 
°
C. The gel was rinsed 
in dH2O and the gel images were taken by using the BioImaging Systems.  
 
2.3.1.5 Western Blotting analysis 
Proteins samples were electrophoresed on SDS PAGE as described in section 
2.3.1.3. The proteins were transferred onto PVDF membrane (Bio-Rad) using 
Bio-Rad MiniProtein Trans Blot system. Before transfer the membrane was 
equilibrated by pre-wetting the membrane in 100 % methanol for 30 Sec. the 
membrane was washed with distilled water for 5 min. the membrane, sponges, 
gels Whatman paper were equilibrated in pre-chilled transfer Buffer for 15 min 
and was assembled. Protein was electro-blotted onto the PVDF membrane at 100 
V constant for 90 min in pre-cooled Transfer Buffer or at 4 
°
C, 35 V (constant 
voltage) overnight in pre-cooled Transfer Buffer using Power Pac Basic HC 
300W (Bio-Rad). 
 
2.3.1.6 Probing the blot with antibodies  
After the protein was transferred into PVDF membrane. The PVDF membrane 
was incubated (with shaking) in the blocking Solution at room temperature for 60 
min and then rinsed with TBStween-20 (3 times for 50 min). The PVDF 
membrane was then incubated (with shaking) over night at 4 
°
C in human Pan-
Cadherin primary antibody (1:750 dilution prepared in TBSTween-20). The 
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membrane was rinsed for 5 min three times with 10 mL TBSTween-20. Then the 
membrane was incubated for 60 min in Goat anti mouse secondary antibody IgG-
HRP (diluted at 1in 3000 times in TBSTween-20). The membrane was rinsed 
three times (7 min each) with TBSTween-20 for 7 min each while shacking. The 
membrane was placed into dark place in UVP BioImaging system making sure 
the side with the blotted protein is upright. Super Signal West Pico 
Chemiluminescent substrate was prepared by mixing 1:1 of solution A and 
Solution B as per manufacture’s instructions (Thermo Scientific) and the substrate 
mixture was applied over the membrane making sure that the membrane was 
covered with substrate. The membrane was imaged using UVP Transilluminator 
and photographed with BioImaging Systems Chemi HR 410 Camera with 
different time 1-5 min. 
 
2.3.1.7 Preparation of protein samples for by LC MS/MS analysis 
The MCF-7 and MCF1-2A cell lines were cultured and labelled with 
13
C6 L-
Lysine-2HCl and L-Arginine-HCl amino acids, respectively as described in 
section 2.3. The plasma membrane proteins were extracted as described in section 
2.3.1. 100 μg of the protein samples were resolved in 12 % SDS-PAGE following 
the method described in section 2.3.1.3, the gel (Figure 2.1) was stained using 
Coomassie staining solution for 60 min. 
 
After destaining the gel in destaining solution, the lane containing the protein 
sample was cut into 11 sections using a sterile blade. The samples were 
transferred into sterile 1.5 mL Eppendorf tubes and sent (on dry ice) for LC 
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MS/MS analysis to the Central proteomics facility Sir William Dunn Pathology 
School, South Parks Rd, University of Oxford, UK.  
 
2.3.1.7.1 Proteomics data analysis  
Data analysis was preformed using Thermo Proteome Discoverer software 
(version1.4). Membrane, extracellular, cell surface proteins and unclassified 
proteins were generated using analysis software to identify global function of all 
available proteins. All the information such as IPI human identification numbers, 
score, coverage, cellular component and the quantitative of the proteins were 
received in excel spreadsheet file. 
 
The data was analyzed using in silico bioinformatics tools (Figure 2.1).  
The following tools were used: EMBL-EBI Genes Expression Atlas 
(http://www.ebi.ac.uk/gxa/home;jsessionid=257BDF22B95699B6F25E948C1F9
C33C1), iHOP (http://www.ihop-net.org/UniPub/iHOP/), TiGER 
(http://bioinfo.wilmer.jhu.edu/tiger/), Uniprot (http://www.uniprot.org), The 
Maxquant Database (MaxQB) (http://maxqb.biochem.mpg.de/mxdb/) and 
GeneHub-GEPIS (http://research-public.gene.com/Research/genentech/genehub-
gepis/genehub-gepis-search.html). 
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Figure 2. 1: Experimental strategy for the SILAC method for MCF-7 and MCF-12A. The cells 
were grown in media containing heavy and light isotope, respectively. The cell surface proteins 
were isolated and quantified, mixed in 1:1 a ratio and resolved by 1D SDS-PAGE. The protein 
fractions were excised and send to the Central proteomics facility Sir William Dunn Pathology 
School, South Parks Rd, University of Oxford, UK for LC-MS/MS analysis. The data received 
from the Central proteomics facility was analyzed by using bioinformatics tools. 
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2.4. Identification of known biomarkers for breast cancer 
Computational tools were used to determine genes that were differentially 
expressed in breast cancer. The search engines used were PubMed, PubMed 
Central, Google Scholar, Science direct, springer Link and nature. The search 
terms included breast cancer, biomarkers and differential expression of breast 
cancer genes. The expression of identified breast cancer genes were further 
analyzed for using Database for Annotation, Visualization and Integrated 
Discovery (DAVID) version 6.7. Nineteen known biomarker genes were 
identified from literature searches and these were further analyzed using DAVID 
to determine the expression profile of these genes in different tissues and to 
validate their expression levels in breast cancer. 
 
2.5 Primers design for qRT-PCR  
In this study primers for the selected genes listed in Table 2.9 were designed to 
amplify a region of the coding sequence of each target gene using default 
parameters with the exception of PCR product size parameter, which was set to 
select primers to amplify product in the range 100 - 233 bp. The online Primer3 
Plus software (http://www.bioinformatics.nl/cgi-bin/primer3plus/primer3plus.cgi) 
was used to design the primers. The mRNA sequences for all the genes were 
obtained from the National Centre for Biotechnology Information (NCBI). The 
primers were purchased from Inqaba Biotech (Pretoria, South Africa). 
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Table 2. 9: Oligonucleotide primers sets for genes encoding biomarkers. The expected product 
size and calculated annealing temperature for qRT-PCR reaction is also indicated. 
 
Abbreviations: 5= 5 prime; 3= 3 prime; bp = base-pair F P = forward primer; R P = revers 
primer; TA = annealing temperature; A = adenosine; C = cytosine; G = guanosine; T = thymidine. 
 
Gene name  
Ensemble Accession 
Number 
Primer 
Name 
Primer Sequence (5-3) Product Size (bp) TA (
°C) 
FOXA1 ENSG00000129514 
F P FOXA1 AAGGCATACGAACAGGCACT 
161 bp 59 
R P FOXA1 GTGTTTAGGACGGGTCTGGA 
CK19 ENSG00000171345 
F P CK19 TCGAGGGACAGGAAGATCAC 
158 bp 59 
R P CK19 ATTGGCAGGTCAGGAGAAGA 
HER-2 ENSG00000146648 
F P HER-2 AGTACCTGGGTCTGGACGTG 
194 bp 59 
R P HER-2 CTGGGAACTCAAGCAGGAAG 
GFRA1 ENSG00000151892 
F P GFRA1 AGACCACCACTGCCACTACC 
219 bp 59 
R P GFRA1 TTGTGGTTATGTGGCTGGAA 
EPHB4 ENSG00000196411 
F P EPHB4 TATTCGGACAAACACGGACA 
233 bp 59 
R P EPHB4 TCTTGATTGCCACACAGCTC 
NENF ENSG00000117691 
F P NENF GGTAGCCAAGATGTCCTTGGA 
186 bp 59 
R P NENF TCAGGCTTGAAGTCCAGGTTA 
PTGES2 ENSG00000148334 
F P PTGES2 GCAGGGCTGAGATCAAGTTC 
175 bp 59 
R P PTGES2 GCCTTCATGGCTGGGTAGTA   
GAPDH ENSG00000111640 
F P GAPDH ACCCACTCCTCCACCTTTG 
178 bp 59 
R P GAPDH CTCTTGTGCTCTTGCTGGG 
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The primers were reconstituted in 1 X TE Buffer and stored at -20 
°
C until 
required.  
 
2.6 RNA Isolation:  
The isolation of total RNA was carried out with the use of NucleoSpin® 
RNA/protein Macherey-Nagel kit, according to the manufacture’s data sheet.  
 
The MCF-7 and MCF-12A cell lines were grown in DMEM:F12 media and upon 
reaching approximately 90 % confluency as described in section 2.2.3 The cell 
cells were trypsinzed with 3 mL 0.25 % trypsin solution as described in section 
2.2.4. The pellet was washed with cooled 1 X PBS to remove trace trypsin prior to 
RNA isolation  
 
The cells were lysed by adding 350 μL RP1 Buffer and 7 μL TCEP to the cells. 
The cells were vortexed vigorously for 1 min and the lysate was filtered through a 
NucleoSpin®
 
Filter spin column (violet ring) into a collection tube by 
centrifugation at 11 000 xg for 1 min at 25 
°
C using an Eppendorf 5417 R 
microcentrifuge a F45-30-11 rotor. NucleoSpin®
 
Filter was discarded and 350 μL 
70 % ethanol was added to the filtrates (homogenized lysate). For each 
preparation, a NucleoSpin® RNA/protein column (light blue ring) was prepared 
by placing the column in a collection tube.  
 
The lysate was added and centrifuged at 11 000 xg for 30 Sec at 25 
°
C. The 
NucleoSpin® RNA/protein column was placed into a new collection tube. The 
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RNA was purified by adding 350 μL of Membrane Desalting Buffer (MDB) to the 
column and centrifuged the column at 11 000 xg for 1 min. The DNA present on 
the column was digested by adding 95 μL of rDNase reaction mixture (10 μL 
reconstituted rDNase and 90 μL reaction Buffer rDNase) to column and 
incubating the column at 25 
°
C for 15 min. The first wash of the column was 
achieved by adding 200 μL RA2 Buffer to NucleoSpin® RNA/protein column 
and centrifuging at 11 000 xg for 30 Sec. The column was placed into a new 2 mL 
collection tube. The second wash was achieved by adding 600 μL RA3 Buffer 
onto NucleoSpin® RNA/protein column and centrifuging at 11 000 xg for 30 Sec 
and the flow-through was discarded and the column was returned to the collection 
tube. A volume of 250 μL RA3 Buffer was added to the NucleoSpin® 
RNA/protein column and centrifuged at 11 000 xg for 2 min. 
 
The NucleoSpin® RNA/protein column was placed into a sterile 1.5 mL RNase-
DNase free collection tube. RNase free water (40 μL) was added to the column 
and centrifuged at 11 000 xg for 1 min. The flow-through collected contained the 
total RNA. The RNA sample was quantified as described in section 2.6.4. The 
sample was stored at -80 
°
C for further use. 
 
2.6.1 Preparing 1 % gel agarose for RNA electrophoresis 
A 1 % (w/v) agarose gel was prepared by adding 1 g of agarose powder to 1 X 
TBE Buffer. The mixture was heated until the agarose was completely melted. 
The mixture was cooled down to about 50 - 60 
°
C. Upon cooling a GelRed nucleic 
acid stain (BioTIUM) was added to a final concentration 0.03 X. The casting tray 
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and the comb were washed with Sodium hypochlorite. The gel solution was 
poured and solidified in a horizontal gel-casting tray. 
 
2.6.2 Agarose gel electrophoresis of RNA 
The RNA was electrophoresed on 1 % agarose gels as mentioned in section 2.6.2. 
To assess the integrity of the RNA, the samples were prepared by adding 3 μg of 
RNA to and 1 μl of 6 X loading Buffer (Fermentas). The samples were heated at 
65 
°
C for 4 min using Thermomixer comfort 1.5 mL before loading into the wells 
of the gel. GeneRuler 1Kb DNA ladder (Fermentas) was loaded to estimate the 
size of RNA fragments. The samples were loaded into 1 % agarose gel gel 
buffered with 1 X TBE Buffer (pH ~ 8.3) and electrophoresed at 90 V constant for 
60 min using a Power Pac Basic HC 300W system (BIO-RAD). The gel was 
imaged using the UVP Transilluminator and photographed with the BioImaging 
Systems Chemi HR 410 Camera using SYBER Gold filter at 302 nm. 
 
2.6.3 Synthesis of cDNA 
cDNA was synthesized from total RNA of MCF7 and MCF12A using transcriptor 
First Strand cDNA synthesis Kit (Roche) according to manufacturer’s data sheet 
instructions. Briefly, the following components were mixed added as follows; 
Achored-oligo (dT) (2.5 μM) was added to 1 μg of RNA and made up to a total 
volume of 13 μL was made by adding PCR grade water. The template-primer 
mixture was denatured by heating the tube at a 65 
°
C for 10 min in a thermal 
block cycler with a heated lid (GeneAmp PCR system 2700, Applied Biosystems) 
and then placed on ice. Transcriptor reverse transcriptase reaction Buffer (1 X), 
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Protector RNase Inhibitor (20 U), Deoxynuleotide Mix (1 mM) and Transcriptor 
Reverse Transcriptase (10 U) were added, respectively, to make a final volume of 
20 μL (appendix Table 1). The sample mixture was collected at the bottom of the 
tube by brief centrifugation, after which the tube was heated at 55 
°
C for 30 min. 
Transcriptor Reverse Transcriptase was inactivated by heating at 85 
°
C for 5 min, 
after which the tube was put on ice to stop the reaction. The cDNA was quantified 
and kept at -20 
°
C until further use. 
 
2.6.4 Quantification of RNA and cDNA 
 2.6.4.1 Determination of RNA quality and quantity using Agilent 
BioAnalzyer  
For RNA Quantification and determination of RNA integrity number (RIN), RNA 
samples were analyzed on an Agilent 2100 BioAnalyzer (Agilent Technologies) at 
the Central Analytical Facility (CAF) in the Department of Genetics, Stellenbosch 
University (appendix Figure: 1 and 2). Briefly, 1 ul of extracted total RNA was 
loaded on a Bioanalyzer chip, and the quality and quantity was measured using 
the default parameters for RNA on the BioAnalyzer. This was done for both 
MCF-7 and MCF-12A. 
 
2.6.4.2 Determination of cDNA and RNA concentration by Nanodrop 
The cDNA and RNA concentrations were determined on a Nanodrop-ND1000 
Spectrophotometer (Thermo Scientific). Briefly, the Nanodrop was setup for 
nucleic acid, and then the calibration was done using distilled water. One 
microletter of this sample was loaded for measurement onto lower measurement 
pedestal. The sample was measured using absorbance at 260/280 to assess the 
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purity of DNA and RNA nm and the ratio of RNA was ~ 2.0 and for cDNA was ~ 
1.8. The concentration of the cDNA and RNA was also determined using this 
method. The measurement of each sample was repeated three times. 
 
2.6.5 Quantitative Real Time Plymerase Chain Reaction (qRT-PCR) 
The cDNA from MCF-7 and MCF-12A cell lines was synthesized through reverse 
transcription method as described in Section 2.3.6, and used as a template for 
amplification of genes using the primers listed in table 2.9. 
 
qRT-PCR reactions were performed on a ABI Prism StepOnePlus™ Instrument 
(Applied Biosystems) using a KAPA SYBR
®
 FAST for ABI Prism
®
 PCR Mix (2 
X) (Kapa Biosystems), according to manufacturer’s datasheet and was optimized 
for all primer combinations. Serial dilutions of known cDNA concentration was 
made from a stock solution and ranged from 200 ng to 0.02 ng of input RNA. 
This was done for each gene to construct a standard curve, which could be used to 
calculate PCR efficiency (indicated in Table 2.10) and to determine template 
concentrations. 200 nM Forward primer and 200 nM Reverse primer were used 
for each reaction in a final reaction volume of 20 μL as indicated below. 
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Table 2. 10: Quantitative Real-Time PCR reaction reagents  
Reagent Final concentration 
KAPA q-PCR Mix (2 X)  1 X 
F. Primers  200 nM 
R. Primers  200 nM 
Template (cDNA)  20 ng/ μL 
PCR-Grade deionized H2O Variable~ 
Final Volume 20 μL 
 
 
The qRT-PCR was set up according to the standard three-step protocol for qRT-
PCR (denaturation, annealing and extension) and subjected to 45 cycles 
consistently. These steps had some variations in annealing temperature depending 
on nucleotide sequences of the gene of interest. The reactions were performed for 
all selected genes with two housekeeping genes for both cell lines MCF-7 and 
MCF-12A. The reactions were performed in a 96-well PCR plate on an ABI Step 
One Plus; at the Central Analytical Facility at the University of Stellenbosch, the 
system was cycled according to the standard parameters (appendix Table 2). The 
reactions were prepared according to the following steps table 2.10. The products 
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were stored at – 20 °C for possible future downstream analysis or electrophoresed 
on 1 % agarose gels. 
 
2.7 Immunohistochemistry (IHC) 
2.7.1 Cell cultures  
The cells were seeded on positive charged glass slides (76 mm x 26 mm; 1.0 mm 
to 1.2 mm thick). The slides were autoclaved prior to seeding the cells. The cells 
were cultured as described in section 2.2.3 until about 80 % confluency were 
reached. The cells were washed three times with 1 X PBS, 3 min each. The cells 
were fixed in 4 % paraformaldehyde (PFA) at 25 
°
C for 20 min. The cells were 
washed with 1 X PBS, for 5 min. The cells were stained with Anti-GFRA1 
antibody (1:500 dilution). All staining, washing and antibody incubations were 
performed in a Leica Bond Autostainer (Leica) at the Histology Laboratory at 
Tygerberg Hospital. 
 
2.7.2 Breast cancer tissues  
The breast cancer tissues were obtained from National Cancer Institute Misurata 
(Libya). Two experienced pathologists (Dr Y. Topov and Dr Fathi Abdalla) 
performed the diagnosis of the tissue samples. Three tissue samples diagnosed as 
stage I, II and III was used in this study.  
 
2.7.2.1 Ethical Approval  
The Ethics Committee of the Stellenbosch University granted ethics approval for 
the use of the human samples in this study (Reference Number: N13/08/118). 
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2.7.3 Fixation and paraffin wax embedding of the tissues  
Briefly; after the cancer tissues was removed surgically the samples were kept 
over night at 25 
°
C in 10 % formalin solution. After the fixation period, the tissues 
were moved to labelled histology cassettes.  
 
2.7.4 Tissues processing  
The tissues were processed through series of solutions using as described in Table 
2.11. 
 
Table 2. 11: Processing protocol for FFPE tissues  
Step Solution  Temperature  Time  
1 70 % Ethanol 25 60 min 
2 90 % Ethanol 25 120 min 
3 100 % Ethanol 25 60 min 
4 100 % Ethanol 25 60 min  
5 100 % Ethanol 25 6 hrs  
6 100 % Xylene 1 25 60 min  
7 100 % Xylene 2 25 2 hrs 
8 Paraffin wax  58 60 min 
9 Paraffin wax  58 60 min  
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2.7.5 Embedding  
Processed tissues were embedded in paraffin wax at 60 
°
C to obtain tissues blocks. 
The tissues blocks were kept at 25 
°
C until sectioning was performed. 
 
2.7.6 Sectioning  
The tissues blocks were quickly frozen and then sectioned using a Leica RM 2125 
RT microtome (Leica) to obtain uniform 5µm section. The sections were placed 
on positive charged glass slides. Three slides were prepared for each tissue 
sample. 
 
2.7.7 Haematoxylin and eosin (H&E) staining  
Prior to staining, slides were placed in an incubator for the wax to melt of the 
tissues. The tissues or cell cultures were stained using a Leica Bond Autostainer 
(Leica) at the Histology Laboratory at Tygerberg Hospital as shown in Table 2.12 
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Table 2. 12: The processes and the solutions for H&E staining. 
Step Solution  Time Repetitions 
] Xylene 10 min X 2 
2 Ethanol (99 %) 5 min X 2 
3 Ethanol (95 %) 2 min X 1 
4 Ethanol (70 %) 2 min X 1 
5 Distilled water 5 sec X 1 
6 Haematoxylin 8 min X 1 
7 Running water 5 min X 1 
8 
Ethanol (1 % acid 
alcohol)  
30 sec X 1 
9 Running water 1 min X 1 
10 Ammonia (0.2 %) 45 sec X 1 
11 Running water 5 min X 2 
12 Ethanol (95 %) 10 dips X 1 
13 Eosin 45 sec X 1 
14 Ethanol (95 %) 5 min X 2 
15 Xylene 5 min X 2 
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2.7.8 Immunohistochemical (IHC) staining 
The slides were stained with Anti-GFRA1 antibody (1:500 dilution). All staining, 
washing and antibody incubations were performed in a Leica Bond Autostainer 
(Leica) at the Histology Laboratory at Tygerberg Hospital as shown in Table 2.13. 
 
Table 2. 13: The IHC staining protocol  
Step        Type Incubation 
Time  
Temperature  Dispense Type  
1 Peroxide Block 5 min Ambient Selected vol. 
2 Bond Wash Solution 0 min Ambient Selected vol. 
3 Bond Wash Solution 0 min Ambient Open 
4 Bond Wash Solution 0 min Ambient Selected vol. 
5 Primary Antibody 15 min Ambient Selected vol. 
6 Bond Wash Solution 0 min Ambient Selected vol. 
7 Bond Wash Solution 0 min Ambient Selected vol. 
8 Bond Wash Solution 0 min Ambient Selected vol. 
9 Post Primary 8 min Ambient Selected vol. 
10 Bond Wash Solution 2 min Ambient Selected vol. 
11 Bond Wash Solution 2 min Ambient Selected vol. 
12 Bond Wash Solution 2 min Ambient Selected vol. 
13 Polymer 8 min Ambient Selected vol. 
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14 Bond Wash Solution 2 min Ambient Selected vol. 
15 Bond Wash Solution 2 min Ambient Selected vol. 
16 Deionized Water 0 min Ambient Selected vol. 
17 Deionized Water 0 min Ambient Selected vol. 
18 Mixed DAB Refine 10 min Ambient Selected vol. 
19 Deionized Water 0 min Ambient Selected vol. 
20 Deionized Water 0 min Ambient Selected vol. 
21 Deionized Water 0 min Ambient Selected vol. 
22 Hematoxylin 5 min Ambient Selected vol. 
23 Deionized Water 0 min Ambient Selected vol. 
24 Deionized Water 0 min Ambient Selected vol. 
25 Deionized Water 0 min Ambient Selected vol. 
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2.7.9 Rehydration  
After the staining the tissues or cells, the samples were rehydrated and cleared 
manually as shown in Table 2.14. 
 
 
Table 2. 14: The rehydration protocol  
Step Solution Duration 
1 70 % alcohol 5 dips 
2 96 % alcohol 5 dips 
3 96 % alcohol 5 dips 
4 99 % alcohol 5 dips 
5 99 % alcohol 5 dips 
6 Xylene Dip for 1 min 
7 Xylene Dip for 1 min 
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2.7.10 Mounting 
PDX mounting medium was used to cover the glass slide. The slide was left to 
dry at 25 
°
C. 
 
2.7.11 The evaluation of the protein expression 
The protein expression in cell lines or cancer tissues was evaluated by microscopy 
using a Zeiss Microscope with objectives at 20 X and 40 X magnifications for 
FFPE slides and 100 X for both cell cultures. 
 
2.8 Design and synthesis of the Oligonucleotides with/ Biotion TEG of 
Molecular beacon probe. 
The use of MBs for RNA detection and localization requires designing the MB for 
specific region of RNA inside the cell. Designing MB involves four steps, the 
loop, stem, fluorophore and the quencher. Loop region is the primary concern for 
designing MBs for intracellular RNA. 
 
The loop of MBs of specific gene was designed by selected an appropriate target 
region on the mRNA sequence obtained from the NCBI database. The probe 
sequence, 20 bp in length, was designed to be complementary to a target 
sequence. The obtained sequence was queried against the NCBI sequence 
database using BLAST 2.2.28 (www.ncbi.nlm.nih.gov/BLAST/) to confirm its 
specificity for the target sequence. 
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The stem portion sequence was designed to contain a 5-7 bp region that was 
complementary to each other to allow hybridization to one another. This region 
was confirmed to be non-complementary to the loop sequence to prevent 
hybridization to the loop. 
 
The sequences were sent to IDT (Integrated DNA technology) for synthesizing 
and modification with Biotin-tetraethylene glycol (TEG-) at 3 end. The MBs 
were synthesized to nmole scale and purified by HPLC. The oligos were prepared 
in 1 X TE buffer (pH 8.0) as per the manufactures instructions. Oligonucleotides 
which represented the complementary sequence of the MB were designed and 
synthesized at Inqaba Biotech (Pretoria, South Africa).  
 
The oligonucleotides were designed using the Primer3Plus software package 
(http://www.bioinformatics.nl/cgi-bin/primer3plus/primer3plus.cgi). It was 
designed to hybridize to 20 base sequence based on selected breast cancer gene 
sequences. The nucleotide codon sequence for each target gene was translated to 
protein sequences by using Expasy bioinformatics resource Portal 
(http://web.expasy.org/translate/) to ensure that the oligo sequence portion is 
located in the same protein sequence. This analysis was also performed to ensure 
that the sequences were completely matched between two sequences (the query 
sequences to a target sequences). The primers sequences were then selected and 
searched using BLASTN 2.2.28 (www.ncbi.nlm.nih.gov/BLAST/). The sequences 
were sent to IDT (Integrated DNA technology) for synthesizing and modification 
with Biotin -tetraethylene glycol (TEG-) at 3 end. The MBs were synthesized to 
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nmole scale and purified by HPLC. The oligos were prepared in 1 X TE buffer 
(pH 8.0) as per the manufactures instructions. Oligonucleotide, which represented 
the complementary sequence of the MB, were designed and synthesized at Inqaba 
Biotech (Pretoria, South Africa).  
 
2.8.1 Activation of molecular beacon oligo’s 
The oligo’s (MB-CK19/Short and MB-CK19/Long) were activated by re-
suspending the oligo’s in 1 X TE buffer (pH 7.5), containing 10 mM DTT. Using 
the Amicon Ultra-0.5 centrifugal filters, CK19 Oligo (500 μL) was centrifuged at 
high speed at 4 
°
C for 5 min. The flow-through was discarded. The remaining 
amount of Oligo was added and the process was repeated yielding about 30 μL of 
the concentrated activated Oligo in the filter. For the washing step, 500 μL of 1 X 
TE was added to the activated Oligo and centrifuged at high speed for 10 min at 4 
°
C. To recover the concentrated Oligo, the centrifugal filter was placed upside 
down into clean microcentrifuge tube and centrifuged at 2000 RPM for 2 min at 4 
°
C. The volume of the recovered concentrated Oligo was measured and finally 
made up to total volume of 640 μL to achieve concentration of 100 μM of the 
CK19-Oligo. The Oligo was kept at -20 
°
C until used. 
 
2.8.2 Preparation of MB-CK19/Short and MB-CK19/Long molecular beacon  
Modified Iowa Black-Oligo (2 μL, 100 μM) with final concentration 200 nM was 
added to Qdot® 525 ITK™ Carboxyl Quantum Dot (100 μL, 1 000 pM) with 
final concentration 100 pM, and dissolved in PBS (892 μL, 1 X). The solution 
was incubated for 5 min at 37 
°
C with shaking. N-Hydroxysuccinimide (NHS) (3 
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μL, 100 μM) was added and incubated for 5 min with shaking at 37 °C. Then 1-
Ethyl-3-(3-dimethylaminopropyl) carbodiimide hydrochloride (EDC) (3 μL, 100 
μM) incubated at 37 °C for 60 min with shaking. The Qdot-MB-CK19 was kept at 
4 
°
C until used. 
 
2.8.3 Fluorescence measurement for Qdot  
To measure the fluorescence intensity of Qdot-MB-CK19 used POLAR star 
Omega Microplate reader. The fluorescence intensity of molecular beacon was 
measured with excitation 355 nm and emission 525 nm. 
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CHAPTER 3 
 
 3.1 Identification and validation of biomarkers for breast cancer  
3.1.1 Introduction  
One of the limitations of current molecular biomarkers for breast cancer is that 
most of the biomarkers can only be used in invasive diagnostic systems. There is 
therefore a need to discover new molecular biomarkers for breast cancer that can 
facilitate the development of non-invasive diagnostic techniques. Currently used 
molecular diagnostic methods for breast cancer such as FISH, IHC and qRT-PCR 
requires biopsy samples, which make the diagnosis highly invasive. Proteins that 
are present on the surface of cancer cells or are shed by cancer cells would make 
ideal biomarkers for the development of non-invasive diagnostic procedures, since 
these biomarkers can be detected in bodily fluids such as blood or urine. 
 
Although numerous studies have been performed to identify biomarkers for 
diseases such as cancer, the most common methods used involved functional 
genomic studies using techniques such as DNA microarrays (Zhang et al., 2013). 
DNA microarrays have made it possible for researchers to estimate the level of 
expression of thousands of genes in a sample of cells or tissue and identify genes 
that can be linked to diseased states. Researchers in the biomedical research fields 
and those working in the clinical diagnostic fields have been quick to adopt this 
powerful research tool. Due to the vast amount of data obtained from these studies 
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accurate analysis and interpretation of the data obtained from DNA microarrays 
studies have provided unique challenges to investigators.  
 
There is some evidence that microarray technology can produce inconsistent 
results mainly due to the associated computational and statistical difficulties. For 
example, in diffuse large B-cell lymphoma it was shown that the survival rate for 
this disease can be predicted based on the expression levels of six genes (Lossos 
et al., 2004, Tarca et al., 2009). However, microarray analysis could not identify 
the same six-gene panel in diseased samples even though PCR results 
demonstrated that these genes were up-regulated in the diseased samples 
(Rosenwald et al., 2002, Shipp et al., 2002).  
 
DNA microarrays assess gene expression at the level of transcription, while 
proteomics assess gene expression at a translational level. Since it is proteins and 
not mRNA molecules that carry out biochemical processes within cells and are 
directly involved in the pathology of diseases, proteomics is a more reliable 
technology to use for the identification of biomarkers.  
 
The aim of this chapter was therefore to identify cell surface proteins that are 
differentially expressed between a human breast cancer cell line (MCF-7) and a 
non-cancerous human breast cell line (MCF-12A), since these proteins can be 
potential biomarkers for breast cancer. The first objective towards this aim was to 
isotopically label cellular proteins of MCF-7 and MCF-12A cells in cell culture 
using SILAC. The second objective was to extract the cell surface proteins from 
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the labelled cells and to perform a comparative proteomics analysis of the 
expression levels of the proteins isolated from MCF-7 and MCF-12A cells. The 
third objective was to use online bioinformatics tools such as GeneHub-GEPIS to 
investigate the expression levels of the putative biomarkers in cancer tissues. The 
fourth objective was to confirm the up-regulation of some of these putative 
biomarkers in the MCF-7 cells by expression analysis using qRT-PCR and IHC.  
 
3.2 Results and Discussion 
3.2.1 The isotopic labelling of MCF-7 and MCF-12A cells 
MCF-12A is a non-cancerous cell line that was derived from human mammary 
gland epithelial cells of a 60-year old Caucasian female, while the MCF-7 cell line 
is a human mammary gland breast adenocarcinoma that was derived from the 
metastatic cancer site of a 69-years old Caucasian female (information obtained 
from ATCC).  
 
MCF-12A cells exhibit typical luminal epithelial morphology, three-dimensional 
growth in collagen, and form domes in confluent cultures. The cells are positive 
for epithelial cytokeratins 8, 14 and 18, and negative for cytokeratin 19. MCF-7 
cells are useful for in vitro breast cancer studies because the cell line has retained 
several ideal characteristics particular to the mammary epithelium. These include 
the ability to process estrogen, in the form of estradiol, via estrogen receptors in 
the cell cytoplasm. This makes the MCF-7 cell line an estrogen receptor (ER) 
positive control cell line (information obtained from ATCC).  
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The successful SILAC labelling of cells in cell culture medium requires that the 
cells be cultured for a period equivalent to 6 to 8 doubling events (Ong et al., 
2002, Munday et al., 2012). To optimise the culture period in SILAC medium so 
that optimal labelling can be achieved, MCF-7 cells were cultured in “heavy” 
labelling media (media containing 
3
C6 L-Lysine-2HCl) for four weeks.  
 
The cells were harvested as described in section 2.3.1 and the total cellular 
proteins were isolated from the cells as described in section 2.3.1. The protein 
sample was quantified using the Qubit® 2.0 Fluorometer (Invitrogen) and 20g of 
the protein sample was analysed by 1D SDS PAGE (Figure 3.1) as described in 
section 2.3.1.3. To confirm that the cells were sufficiently labelled, protein bands 
that stained intensely with Coomassie Brilliant blue (Figure 3.1, lane A) was 
excised from the gel and the gel slice was sent to the Central Proteomics Facility 
at the Sir William Dunn Pathology School (University of Oxford, UK) for LC-
MS/MS analysis. This analysis demonstrated MCF-7 cells were sufficiently 
labelled in SILAC medium after a four-week culture period. Consequently, MCF-
7 and MCF-12A cells were metabolically labelled in cell culture with “heavy” 3C6 
L-Lysine-2HCl and “light” L-Arginine-HCl stable isotopes, respectively (as 
described in section 2.3). 
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Figure 3. 1: SDS-PAGE of SILAC labelled proteins isolated from MCF-7 cells. MCF-7 were 
labelled with 
3
C6 L-Lysine-2HCl. Lane M represents the protein ladder. Lane A shows the proteins 
isolated from MCF-7. Section C represents the area in the gel that was excised for LC-MS/MS 
analysis. 
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3.2.2 The extraction of cell membrane proteins 
The Pierce® Cell surface protein isolation Kit from Thermo Scientific was used to 
isolate cell surface proteins from MCF-7 and MCF-12A cells following SILAC 
labelling as described in section 2.3.1. This Kit allows for the isolation of cell 
surface proteins based on biotin-avidin affinity. The cell surface proteins are first 
biotinylated by incubating the cells with EZ-Link Sulfo-NHS-SS-Biotin. The cells 
are lysed with a mild detergent and the labelled proteins are pulled down with 
NeutrAvidin Agarose. The bound proteins represent the cell membrane or cell 
surface proteins. 
 
The cell or plasma membrane is the outermost layer of a cell and consist of a 
phospholipid bilayer. The membrane proteins are anchored in membranes and 
each protein has specific function and that often required them to extend beyond 
the membrane surface (Shen et al., 1997). 
 
 Some membrane proteins (peripheral proteins) are on the outside of the 
membrane. These proteins are usually involved in cell-to-cell communications 
(Mader 2011, Shukla et al., 2012). Other membrane proteins are positioned on the 
inside of the cell membrane and can be involved intracellular signaling processes 
or anchoring cytoskeletal proteins to the cell membrane. Some membrane proteins 
(integral proteins) are located within the phospholipid bilayer (Mader 2011). 
Membrane proteins serve a variety of key biological functions, such as cell-to-cell 
communication, receptor-mediated signal transduction, and selective transport 
(Shukla et al., 2012). During disease development plasma membrane proteins can 
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undergo posttranslational modifications (PTMs) which is crucial for pathological 
development of the diseased cell or tissue (Shukla et al., 2012). The expression 
levels of membrane proteins can also be affected to facilitate the new 
pathophysiology of the diseased tissue. Since these proteins are exposed on the 
surface of the cell, they are ideal biomarkers for the diagnosis of the disease. 
Membrane proteins with functional domains exposed to the extracellular 
environment such as integral membrane proteins has been exploited in prognostic 
and predictive diagnosis of patients (Kohnke et al., 2009). These proteins can 
potentially be detected on the surface of circulating tumour cells or be shed from 
the cells ending up in the serum and can thus facilitate the development of non-
invasive diagnostic methods. These proteins can also serve as targets for the 
delivery of therapeutic agents. 
 
To confirm the extraction of cell membrane proteins Western blotting (as 
described in section 2.3.1.6) was performed using the pan-cadherin antibody. Pan-
cadherin is a transmembrane glycoprotein, belonging the cadherin family of 
proteins. The cadherin proteins are calcium-dependent and acts in cell-cell 
adhesion. Pan-cadherin was chosen as cell membrane reference protein as it is 
expressed as an integral protein in many cell types (Patel et al., 2003, Wheelock et 
al., 2003, Paredes et al., 2004, Hulpiau et al., 2009, Paredes et al., 2012). 
 
The Pierce® Cell Surface Protein Isolation Kit separate the total cellular protein 
lysate into a membrane and cytosolic fraction. Twenty microgram (20 g) of the 
cell surface and cytosolic proteins were resolved by 1D SDS-PAGE and stained 
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using Coomassie Brilliant Blue (Figure 3.2). The Coomassie Brilliant Blue 
stained gel shows equal protein loadings for the membrane and cytosolic fractions 
for both MCF-7 and MCF-12A cell lines. The Western blot (Figure 3.3) using the 
pan-cadherin antibody shows the detection of a 132 kDa protein in the membrane 
fractions of MCF-7 and MCF-12A cells (Figure 3.3; lanes A and C, respectively). 
This protein was not detected in the cytosolic fractions of both MCF-7 and MCF-
12A cells (Figure 3.3; lanes B and D, respectively). The molecular weight of the 
protein detected in the membrane fractions of MCF-7 and MCF-12A cells 
correspond to the expected molecular weight of pan-cadherin. This suggested that 
the cytosolic fraction was free of cell membrane proteins and that the extraction of 
cell membrane proteins was successful.  
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Figure 3. 2: 1D SDS-PAGE of membrane and cytosolic proteins isolated from MCF-7 and MCF-
12 cells. Lane M represents the protein molecular weight marker, lane A shows the membrane 
protein fraction of MCF-7 cells, lane B shows the cytosolic protein fraction of MCF-7 cells. Lane 
C shows the membrane protein fraction of MCF-12A cells, lane D shows the cytosolic protein 
fraction of MCF-12A cells.  
 
 
 
Figure 3. 3: Western blot analysis of membrane and cytosolic fractions of MCF-7 and MCF-12A 
cells using the Pan-cadherin antibody. Lane M represents the protein molecular weight marker, 
lane A shows the membrane protein fraction of MCF-7 cells, lane B shows the cytosolic protein 
fraction of MCF-7 cells. Lane C shows the membrane protein fraction of MCF-12A cells, lane D 
shows the cytosolic protein fraction of MCF-12A cells.   
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3.3 Characterization of membrane protein samples by LC-MS/MS 
An equal amount (i.e. 20 g of each) of the membrane protein fraction isolated 
from MCF-7 (labelled with 
3
C6 L-Lysine-2HCl) and MCF-12A (labelled with L-
Arginine-HCl) cells were mixed in a 1:1 ratio. The protein mixtures were 
analysed on a 12 % SDS-PAGE gel (Figure 3.4). The lane representing the mixed 
protein sample was divided into 10 sections and excised as shown in Figure 3.4; 
lane B. The gel slices were sent to the Central Proteomics Facility at the Sir 
William Dunn Pathology School (University of Oxford, UK) for LC-MS/MS 
analysis.  
 
 
 
Figure 3. 4: SDS-PAGE analysis of mixed membrane protein fractions isolated from MCF-7 and 
MCF-12A cells. MCF-7 and MCF-12A cells were differentially labelled in SILAC medium, the 
membrane proteins of the cells were isolated, mixed in a 1:1 ratio and analysed by SDS-PAGE. 
Lane M represents the protein marker and lane B shows a mixture of the labelled of MCF-7 and 
MCF-12A proteins. M1 to M10 represent the individual sections of gel that was excides and sent 
for LC MS/MS analysis. 
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3.3.1 Identification and quantitation of proteins in the membrane fraction 
A total of 2831 proteins were identified by the LC-MS/MS from the 10 gel 
sections. This analysis was done at the Central Proteomics Facility at the Sir 
William Dunn Pathology School (University of Oxford, UK) using MaxQuant 
Software. MaxQuant analysis is a quantitative proteomics software package 
designed for analyzing large mass-spectrometric data sets and provides a large 
amount of information on the protein sample, but of importance in this study is 
the information on the identity of the proteins in the sample, the cellular location 
of each protein and the relative expression levels of each protein in the two 
samples (MCF-7 and MCF-12A). The proteins were categorized based on their 
locations within the cells as shown in Figure 3.5. The locations of 13 % of the 
proteins were unknown (Unclassified Proteins), while 46 % (or 1289 proteins) 
were classified as Cell surface or Extracellular or Membrane (CEM) Proteins and 
41 % (or 1170 proteins) were Cytoplasmic Proteins. Of the 46 % CEM proteins, 
10 % (or 271 proteins) are exclusively located on the cell surface, extracellular or 
membrane and 36 % (or 1018 proteins) can also be located in the cytoplasm. 
Although the Western blot in Figure 3.3 showed that the cytosolic fraction did not 
contain membrane proteins, this result suggests that the membrane fractions 
contained Cytoplasmic proteins as well. Based on the sequence analysis of several 
eukaryotic genomes it is estimated that 30 % of the total protein content of a cell 
are membrane proteins (Qoronfleh et al., 2003). Since 46 % of the proteins in 
membrane fractions were CEM proteins, it can be concluded that the attempt to 
isolate the membrane proteins from MCF-7 and MCF-12A cells resulted in a 
membrane fraction that was significantly enriched for membrane proteins, but still 
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contained some cytosolic proteins. It can also be concluded that no membrane 
proteins were lost in the separation of the membrane and cytosolic proteins since 
the marker for membrane proteins (pan-cadherin) indicated that no membrane 
proteins were present in the cytosolic fraction. 
 
 
 
 
 
 
Figure 3. 5: Intracellular locations of proteins identified by LC-MS/MS. The proteins from 10 
fractions were analysed and classified according to their location in the cells as Cell surface or 
Extracellular or Membrane (CEM) and Cytoplasmic Proteins. Unclassified proteins are proteins 
with unknown cellular localization.  
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The focus of this study was to identify membrane proteins that are differentially 
expressed between MCF-7 and MCF-12A cells. It is for this reason that proteins 
that are exclusively expressed in the cytoplasm were excluded from further study. 
Figure 3.6 is a Venn diagram showing the distribution of the CEM proteins into 
the three categories (Cell surface, Extracellular and Membrane). The majority 
(212) of these proteins are exclusively classified as cell membrane proteins and 16 
proteins are Extracellular proteins. The other proteins are classified into more than 
one of these grouping.  
 
 
 
 
Figure 3. 6: Venn diagram showing the distribution of the 271 CEM proteins.  
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In order to identify CEM proteins that are highly overexpressed in MCF-7 cells as 
compared to MCF-12A cells, a further analysis of the LC-MS/MS data was 
performed. This was done using two parameters (the ratio of “Heavy/Light” 
counts and the “Score”) generated by MaxQuant analysis.  
 
The ratio of “Heavy/Light” counts gives an indication of the comparative 
expression levels of the proteins between the two samples (MCF-7 and MCF-
12A). A high “Heavy/Light” ratio, suggest that the expression of the “Heavy” 
labelled proteins (isolated from MCF-7 cells) was significantly higher compared 
to the “Light” labelled proteins (isolated from MCF-12A cells). If the ratio of 
“Heavy/Light” count is equal to 1, it means that the relative expression levels of 
the “Heavy” labelled proteins (isolated from MCF-7 cells) were equal to the 
“Light” labelled proteins (isolated from MCF-12A cells) and that the expression 
of the these proteins are not different between the two cell lines. For the purpose 
of this study, if the “Heavy/Light” ratio was between 1 and 2, the protein 
expression levels were considered to be equivalent in the two cell lines. If the 
“Heavy/Light” ratios were lower than 1, then the expression of the protein was 
considered to be lower in MCF-7 cells as compared to MCF-12A cells. If the 
“Heavy/Light” ratios were 2 or higher, the protein expression levels were 
considered to be higher in MCF-7 cells as compared to MCF-12A cells. Of the 
2831 proteins identified in this study, 19 % had a “Heavy/Light” ratio of 2 or 
higher. This 19 % represents the proteins that are overexpressed in MCF-7 cells as 
compared to MCF-12A cells. Thirty-five percentile (35 %) had a “Heavy/Light” 
ratio below 1 and 16 % had “Heavy/Light” ratio below between 1 and 2. This 
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implies that expression levels 35 % of the proteins were down regulated and 16 % 
of the proteins were unchanged in MCF-7 cells relative to MCF-7 cells. Although 
this study identified 2831 proteins from the cells, LC-MS/MS analysis produced 
“Heavy/Light” counts for only 1969 (or 70 %) of the proteins. This implies that 
30 % of the proteins were not labelled with the SILAC media. 
 
The second parameter that was considered was the “Score”, which is a confidence 
indicator for the accurate identification of a protein by MS. The higher the 
“Score”, the higher the probability that the identification was accurate and vice 
versa. The “Score” also gives an indication of the relative abundance of the 
protein in the sample. Proteins that are more abundant in the sample will have a 
higher “Score”. It was essential to consider the relative abundance of the potential 
biomarker proteins, since low abundant proteins will not be suitable biomarkers 
proteins. 
 
To identify potential biomarker proteins that are over expressed in MCF-7 cells, 
the 271 CEM proteins that are exclusively located on the cell surface were ranked 
based on “Heavy/Light” ratios. Table 3.1 is showing a list of proteins with the 
highest (top 10) “Heavy/Light” ratio. Isoform 2 of GDNF family receptor alpha-1 
(GFRA1) had the highest “Heavy/Light” ratio of 131.06, while Ectonucleotide 
pyrophosphatase/ phosphodiesterase family member 1 (ENPP1) had the lowest 
“Heavy/Light” ratio of 2.4. The abundance score for GFRA1 was 456.42, 
however other proteins e.g. Ephrin type-B receptor 4 (EPHB4) had higher 
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(1079.9) abundance scores, but lower “Heavy/Light” ratios as compared to 
GFRA1. 
 
Table 3. 1: Top 10 genes with the highest ratio of “Heavy/Light” counts.  
NO Accession Description 
Score 
(abund
ance) 
Heavy/ 
Light 
1 P56159-2 
Isoform 2 of GDNF family receptor alpha-1 
GN=GFRA1 (GDNF). 
465.2 131.066 
2 P54760 Ephrin type-B receptor 4 GN=EPHB4. 
1079.9
9 
6.338 
3 Q8N2K0 Monoacylglycerol lipase ABHD12 GN=ABHD12. 117.38 5.541 
4 F5GYD3 
Neuronal cell adhesion molecule GN=NRCAM 
(KIAA0343; MGC138845; MGC138846). 
1027.1
6 
5.399 
5 H7C5L1 
Prostaglandin E synthase 2 (Fragment) 
GN=PTGES2. 
575.18 3.877 
6 F8VR84 
UPF0160 protein MYG1, mitochondrial 
GN=C12orf10. 
44.92 3.859 
7 Q9UMX5 
Neudesin GN=NENF, CIR2; NEUDESIN; SCIRP10; 
SPUF. 
253.8 3.738 
8 Q9Y6I9 
Testis-expressed sequence 264 protein GN=TEX264 
(FLJ13935, ZSIG11). 
367.93 3.551 
9 Q00765 
Receptor expression-enhancing protein 5 
GN=REEP5 (DP1, TB2, D5S346, C5orf18). 
384.27 2.977 
10 P22413 
Ectonucleotide pyrophosphatase/phosphodiesterase 
family member 1 GN=ENPP1 (M6S1; NPP1; NPPS; 
PC-1; PCA1; PDNP1). 
265.17 2.402 
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3.4 Biomarker validation  
3.4.1 In silico analysis of the expression levels of potential biomarkers 
The candidate biomarkers obtained using proteomics analysis were subjected to 
further study using bioinformatics tools, in particular GeneHub-GEPIS, in an 
effort to investigate the potential of these CEM proteins as biomarkers for breast 
cancer. GenHub-GEPIS is an online bioinformatics tool that can be used to study 
gene expression patterns in healthy and cancer tissues based on human and mouse 
expression sequence tag (EST) abundance (Zhang et al., 2007). GeneHub-GEPIS 
calculates (represented as digital expression unit or DEU) the normalized gene 
expression levels across a large panel of tumour and healthy tissues. This tool 
defines the genomic structures based on mRNA transcript sequence and protein-
coding genes using transcripts from several reliable sources, such as sequences 
from RefSeq, Ensemble genes and proteome (http://research-
public.gene.com/Research/genentech/genehub-gepis/index.html). 
 
The expression patterns of all 10 potential biomarkers (listed in Table 3.1) were 
investigated in 40 different healthy (normal) and tumour tissues using GeneHub-
GEPIS analysis. Although all these biomarkers were up-regulated in breast cancer 
tissue, 6 of these potential biomarkers (ABHD12, NRCAM, MYG1, TEX264, 
REEP5 and ENPP1) also demonstrated expression in the normal breast tissue 
(appendix Figure 3). Consequently, these genes were not studied further. Figure 
3.7 show the expression patterns of the genes encoding the 4 potential biomarkers 
(GFRA1, NENF, EPHB4 and PTGES2) and genes encoding 3 known biomarkers 
(HER-2/ERBB2, FOXA1 and CK19). Figure 3.7 show that all these genes are over 
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expressed in breast cancer tissue as compared to normal breast tissue. GFRA1 
(Figure 3.7. A) is highly expressed (DEU = 102.57) in breast cancer tissue. 
Although, this gene is also up-regulated in 4 other cancers (bone marrow, brain, 
kidney and testis), the expression levels in breast cancer is significantly higher in 
beast cancer compared to the other cancers. GFRA1 is up-regulated 6 normal 
tissues (brain, eye, muscle, nervous system, skin and spleen), but the expression 
level in breast cancer is still significantly higher in beast cancer. This expression 
pattern of GFRA1 compares favourably to that of the known biomarkers. 
Although HER-2/ERBB2 is highly expressed (DEU = 315.03) in breast cancer 
tissue, it is also expressed in 14 normal tissues and over expressed in 21 other 
cancer tissues. FOXA1 is expressed in only 3 normal tissues, but is also over 
expressed in 9 other cancer tissues. However, the expression level for FOXA1 is 
higher in prostate cancer and some normal tissues (e.g. peripheral nervous system) 
as compared to breast cancer tissue. CK19 shows expression in normal beast 
tissue as well. In addition it is also expressed in 14 other normal tissues and 21 
cancer tissues. 
 
The DEU values for NENF, EPHB4 and PTGES2 were 14.65, 40.96 and 51.28, 
respectively. Although NENF, EPHB4 and PTGES2 was over expressed in breast 
cancer tissue as compared to normal breast tissue, these genes were also up-
regulated in other cancerous and normal tissues. NENF was up-regulated in 11 
normal tissues and 10 other cancer tissues. EPHB4 was up-regulated in 12 normal 
tissues and 20 other cancer tissues. PTGES2 was up-regulated in 20 normal 
tissues and 22 other cancer tissues.  
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Based on GeneHub-GEPIS analysis, GFRA1 would be a more selective biomarker 
for breast cancer compared to NENF, EPHB4 and PTGES2. This data also suggest 
that GFRA1 would be a more promising biomarker than the known biomarker 
genes HER-2/ERBB2, FOXA1 and CK19. BRCA2 is a very prominent breast 
cancer biomarker; unfortunately, no expression analysis data was available for 
this gene and therefore the comparison to GFRA1 could not be done. 
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Figure 3. 7: GeneHUB-GEPIS charts showing the expression profile of 4 potential biomarker genes and 4 control biomarkers in 40 different tissues. A, B, C 
and D shows the expression patterns of GFRA1, NENF, EPHB4 and PTGES2, respectively. E, F and G charts showing the expression of 3 control biomarkers 
(HER-2/ERBB2, FOXA and CK19). The blue bar displays the expression in normal tissue and the yellow bar shows the expression in tumour tissues. The 
expression level is represented as a digital expression unit (DEU) values. The expression levels in normal and cancerous breast tissue are indicates in a red box.  
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3.4.2 Expression analysis of potential biomarkers using qRT-PCR 
The expression levels of 4 potential biomarker genes (GFRA1, NENF, EPHB4 
and PTGES2) were investigated in MCF-7 and MCF-12A cells using qRT-PCR. 
The expression levels of five positive control genes GAPDH, BRCA2, HER-2, 
CK19 and FOXA1 were also evaluated. GAPDH is a commonly used reference 
gene in qRT-PCR analysis (Jain et al., 2006), while BRCA2, HER-2, CK19 and 
FOXA1 are known molecular biomarkers for breast cancer (Grunewald et al., 
2000, Radojicic et al., 2011, Faheem et al., 2012). Primer sequences for the 
biomarker genes (FOXA1, CK19, HER-2, BRCA2, PTGES2, GFRA1, NENF and 
EPHB4) were designed based on the gene sequences as shown in section 2.5, 
while primer sequences for the reference gene, GAPDH, were obtained from 
literature (Lecke et al., 2013). 
 
MCF-7 and MCF-12A cells were cultured as discussed in section 2.2.3 and 
mRNA was extracted from these cell lines and converted to cDNA as described in 
section 2.6.3 The RNA integrity, quality and quantity was determined using a 
BioAnalyzer.  
 
qRT-PCR reactions were done using serial dilutions (with concentrations ranging 
from 0.02 ng to 200 ng) of the synthesized cDNA to establish a standard curve for 
each gene and to determine the efficiency of the PCR reactions. Figure 3.8 shows 
the amplification curves for GAPDH using serial dilutions of cDNA produced 
from MCF-7 and MCF-12A mRNA. The 1/10, 1/00 and 1/1000 cDNA dilutions 
produced superimposable amplification curves for both MCF-7 and MCF-12A 
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cells. This suggests that the expression levels of GAPDH in these two cell lines 
were the same. Melting curve analysis was also performed to verify the specific 
amplification of the target genes. Figure 3.9 shows the melting curves of PCR 
products produced for GAPDH. The presence of only one melting peak in the 
range of 75 
°
C to 90 
°
C indicates specific amplification. Additional peaks will 
indicate the amplification of non-specific PCR fragments, which could be as a 
result of contamination, mis-priming (referring to the annealing of primers to 
cDNA sequences other than the target cDNA) or primer-dimers (primers 
annealing to themselves). The melting curves for FOXA1, CK19, HER-2, BRCA2, 
PTGES2, GFRA1, NENF and EPHB4 also gave a single peak (data not shown), 
suggesting the specific amplification of these genes. 
 
In order to normalize the relative quantification of the biomarkers to reference 
gene, the sets of crossing points for the reference genes were imported into 
Relative Expression Software Tool (REST). The chosen crossing points were 
considered during the calculation process of the software, which allowed for a 
normalization of the target genes in relation to the reference gene, GAPDH. The 
randomization test were performed to determine whether normalization via the 
reference gene were useful. The results of the randomization test displayed the 
factor of regulation and level of significance, which indicated that the reference 
gene were suitable in this experiment. GAPDH is a suitable reference gene as it is 
present in all nucleated cell types and mRNA synthesis of this gene has been 
found to be stable in the two cell lines used in this study.  
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Figure 3. 8: Amplification plot for the reference gene, GAPDH. The red, dark green, and dark 
blue slopes indicate the amplification of GAPDH from MFC-7 cDNA at the 1:10, 1:100, and 
1:1000 dilutions, respectively. The yellow, light green, and light blue slopes indicate the 
amplification of GAPDH from MFC-12A cDNA at the 1:10, 1:100, and 1:1000 dilutions, 
respectively. 
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Figure 3. 9: Melting curve analysis for GAPDH. Melting curve for the housekeeping gene, 
GAPDH, ranging from 65 °C to 95 °C. The red, dark green, and dark blue peaks indicate the 
melting curves of GAPDH from MFC-7 cDNA at the 1:10, 1:100, and 1:1000 dilutions, 
respectively.. The yellow, light green, and light blue peaks indicate the melting curves of GAPDH 
from MFC-12A cDNA at the 1:10, 1:100, and 1:1000 dilutions, respectively.  
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The amplification efficiencies of the qRT-PCR reactions, performed with serial 
dilutions of the templates, are based on the slopes of the standard curves obtained 
from the experiment performed for each gene. Table 3.2 shows the amplification 
efficiencies for GAPDH, FOXA1, GFRA1, NENF, EPHB4 and PTGES2. These 
values ranged from 91 to 98 % and are highly similar, indicating that a similar 
rate of amplification occurred for all these genes. 
 
 
Table 3. 2: PCR amplification efficiencies (EFF) for the potential biomarker genes and the 
reference gene GAPDH.  
GENE EFF in MCF-12A EFF in MCF-7 
GAPDH 96 % 95 % 
FOXA1 95 % 95 % 
CK19 93 % 92 % 
HER-2 91 % 94 % 
BRCA2 96 % 93 % 
GFRA1 94 % 98 % 
EPHB4 96 % 94 % 
NENF 94 % 96 % 
PTGES2 98 % 97 % 
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qRT-PCR was performed for FOXA1, CK19, HER-2, BRCA2, PTGES2, GFRA1, 
NENF and EPHB4 as described in section 2.6.5 on cDNA produced from mRNA 
isolated form MCF-7 and MCF-12A cells. Table 3.3 shows a summary of the 
qRT-PCR results for all 8 genes. Indicated in this table are the crossing points 
(Cp) for the amplifications for all the genes and the fold change in the expression 
levels of these genes in MCF-7 cells relative to the expression levels in MCF-12A 
cells. The results show that FOXA1 is significantly up-regulated in MCF-7 cells, 
with a 40.77 fold increase in the expression level of this gene. The other three 
known biomarker genes (CK19, HER-2 and BRCA2) were also up-regulated with 
fold increases of 26.89, 23.82 and 8.13, respectively as shown in Figure 3.10. The 
results are in agreement with the GeneHub-GEPIS analysis, which also showed 
that FOXA1, CK19 and HER-2 were up-regulated in breast cancer tissues (Figure 
3.7 E, F and G). Amongst the 4 putative biomarker genes identified in this study, 
3 genes (GFRA1, NENF and EPHB4) were up-regulated and PTGES2 was down-
regulated. The fold increase in the expression levels of GFRA1, EPHB4 and 
NENF was 4.59, 3.91 and 1.18, respectively. PTGES2 was down-regulated in 
MCF-7 cells relative to MCF-12A cells, with a fold change of -1.52 (Figure 3.10). 
qRT-PCR results for GFRA1, NENF and EPHB4 supports the proteomics and 
GeneHub-GEPIS data, however, the qRT-PCR results for PTGES2 is not in 
agreement with the proteomics data, since the proteomics results suggest that the 
expression levels of the protein encoded by this gene is significantly up-regulated 
in MCF-7 cells relative to MCF-12A cells. Based on the qRT-PCR results, 
GFRA1, EPHB4 and NENF can potentially be used as biomarkers for breast 
cancer. However, the fold increase in the expression levels for these potential 
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biomarkers were significantly lower compared to the known biomarkers (FOXA1, 
CK19, HER-2 and BRCA2).  
 
 
 
 
 
 
Figure 3. 10: Relative expression ration of 4 known and 4 putative biomarkers. Four biomarkers 
that selected from proteomic databases for cell surface protein expression in MCF-7 breast cancer 
line compare to MCF-12A non-cancer cell line with GAPDH as internal control. 
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Table 3. 3: Descriptive statistics of 8 cancer genes showing differential expression between MCF-
7 and MCF-12A cell lines. 
Gene Sample Mean CT Std. error Fold change p-value 
FOXA1 
 
MCF-12A 
 
21.05 
 
0.05 
 
40.765 
 
0.003 
MCF-7 15.75 0.10 
CK19 
 
MCF-12A 
 
24.23 
 
0.05 
 
26.895 
 
0.001 
MCF-7 19.53 0.05 
HER-2 
 
MCF-12A 
 
21.23 
 
0.07 
 
23.823 
 
0.005 
MCF-7 16.70 0.06 
BRCA2 
 
MCF-12A 
 
18.88 
 
0.08 
 
8.136 
 
0.021 
MCF-7 15.90 0.06 
GFRA1 
 
MCF-12A 
 
33.4 
 
0.06 
 
4.593 
 
0.001 
MCF-7 31.23 0.03 
EPHB4 
 
MCF-12A 
 
28.27 
 
0.07 
 
3.907 
 
0.001 
MCF-7 26.33 0.03 
NENF 
 
MCF-12A 
 
24.27 
 
0.09 
 
1.175 
 
0.258 
MCF-7 24.07 0.13 
PTGES2 
 
MCF-12A 
 
33.57 
 
0.09 
 
-1.516 
 
0.145 
MCF-7 34.20 0.05 
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3.4.3 Immunohistochemistry (IHC) 
To assess the expression levels of GFRA1 protein in MCF-7 and MCF-12A cells 
immunohistochemistry (IHC) was performed on both cell lines using an antibody 
to GFRA1 as described in section 2.7.8. As discussed in section 1.2.4.2.2, ICH is 
often used in the diagnosis of cancer. Figure 3.11 show that the expression of 
GFRA1 was up regulated in the MCF-7 cells as compared to MCF-12A cells. 
This is indicated by the more intense brown stain observed in MCF-7 cells.  
 
This study also evaluated the expression of GFRA1 in FFPE breast tissues of 
three breast cancer patients using ICH. A pathologist (Dr Y Topov, the National 
Cancer Institute Misurata Libya) confirmed the three patient samples used were 
cancerous. The three patients were diagnosed at stage I, stage II and stage III 
breast cancer, respectively. Figure 3.12 A/B, C/D and E/F show immunostaining 
for the stage I, stage II and stage III breast, respectively. The brown stain 
represents the presence of the GFRA1 protein, while blue stain represents the cell 
nuclei. Figure 3.12 show that the GFRA1 protein is expressed in epithelial layer 
of the milk ducts. It is also evident that the expression levels of the GFRA1 
protein increase from stage I to stage III.  
 
This result supports the proteomics data as well as the qRT-PCR data and the in 
silico gene expression analysis. The result obtained further strengthens the 
evidence that GFRA1 could be a potential biomarker for breast cancer. However, 
the expression level of this protein needs to be evaluated in other cancer cell lines 
and cancer patient tissue to determine its specificity for breast cancer.   
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Figure 3. 11: IHC analysis of GFRA1 expression in MCF-7 and MCF-12A cells. A and B show 
MCF-7 and MCF-12A cells, respectively; stained with hematoxylin and eosin (H&E). C and D 
show MCF-7 and MCF-12A cells, respectively; stained with H&E and the GFRA1 antibody. The 
dark purple stain represents the nuclei, while the brown stain represents GFRA1. The black arrows 
point to the localisation of GFRA1. Images were taken at 1000 X magnification 
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Figure 3. 12: IHC analysis of GFRA1 expression in different FFPE tissues from three breast 
cancer patients. A/B, C/D and E/F show immunostaining for the stage I, stage II and stage III 
breast, respectively. The ducts are labelled with red circles in figures (A, C and E). The normal 
cuboidal cells was labelled with red circles in figure B. Myoepthelial cell were indicated with 
green arrows in figures (B, D and F) and the fibrotic cell was appointed with yellow arrow in 
Figure B, whereas the GFRA1 expression in the cells in Figures (B, D and F) was shown with blue 
arrows. The images in Figures A, C and E were taken at 200 X magnifications, whereas the 
images in figures B, D and F were taken at 400 X magnifications.  
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3.5 Summary and Conclusion: 
In this study the cellular proteins of MCF-7 and MCF-12A cells were successfully 
labelled in SILAC medium and the membrane proteins of the labelled cells were 
successfully isolated. The study identified 2831 proteins from these cells. LC-
MS/MS analysis showed that only 70 % of the proteins were labelled and that 
some cytosolic proteins were isolated together with membrane proteins.  
 
A comparative analysis of the relative expression levels of proteins in MCF-7 and 
MCF-12A cells found that 19 % (or 538) of the proteins were over expressed in 
MCF-7 cells. Of the 2831 proteins identified, 46 % were classified as CEM 
proteins localised to the membrane of the cells. Ten percentile (10 %) or 271 of 
the CEM proteins are only expressed in the membrane of cells, while 36 % or 
1018 is expressed in both the membrane and cytoplasm of cells. 
 
This study focussed only on proteins expressed in the membranes of cells and 
therefore proteins that are expressed in both the membrane and cytoplasm were 
excluded. The proteins with the highest (the top 10) differential expression 
between MCF-7 and MCF-12A cells were identified. LC-MS/MS analysis 
showed that GFRA1 was expressed at significantly higher levels in the 
membranes MCF-7 cells as compared to MCF-12A cells. 
 
In silico gene expression analysis using GeneHub-GEPIS online tools was 
performed for the genes encoding the 10 proteins with the highest differential 
expression. GeneHub-GEPIS analysis found that all 10 genes were over expressed 
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in breast cancer tissue. However, 6 of these genes (ABHD12, NRCAM, MYG1, 
TEX264, REEP5 and ENPP1) were also expressed in normal breast tissue. In 
contrast the other 4 genes (GFRA1, NENF, EPHB4 and PTGES2) were only 
expressed in breast cancer tissue and not in normal breast tissue. ABHD12, 
NRCAM, MYG1, TEX264, REEP5 and ENPP1 were excluded as potential 
biomarkers since these genes are also expressed in normal breast tissue, leaving 
only 4 potential biomarker genes (GFRA1, NENF, EPHB4 and PTGES2). 
Amongst the 4 genes, GFRA1 stood out as a good candidate biomarker for breast 
cancer, since GeneHub-GEPIS analysis showed that the relative expression level 
of this gene was higher than the other 3 potential biomarkers. The expression 
profile of GFRA1 generated by GeneHub-GEPIS analysis also compared 
favourably with other known breast cancer biomarkers (HER-2/ERBB2, FOXA1 
and CK19). 
 
An expression analysis of GFRA1 using both qRT-PCR and IHC demonstrated 
that both the gene and the protein encoded by the gene was over expressed in 
MCF-7 cells as compared to MCF-12A cells. These results were in agreement 
with the proteomics data. The expression levels of GFRA1 were also investigated 
by IHC analysis in breast tissue samples of three breast cancer patients. The 
patients represented stage I, II and II breast cancer. IHC analysis showed that 
GFRA1 was expressed in the myoepithelium layer of the milk ducts. There is also 
evidence to suggest that GFRA1 expression levels increase from stage I to III.  
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It can be concluded from this study that GFRA1 is potentially a good candidate 
biomarker for breast cancer. This study show that the gene and protein encoded by 
this gene is over expressed in human breast cancer cell lines and tissue samples of 
breast cancer patients. This is supported by a previous study conducted by 
Esseghir and co-workers which showed that mRNA transcripts of GFRA1 or 
GFR1 was up-regulated in invasive breast carcinomas (Esseghir et al., 2007). 
GFRA1 is a glycosylphosphatidylinositol(GPI)-linked transmembrane cell surface 
receptor for Glial cell line derived neurotrophic factor (GDNF) and mediates the 
activation of the Rearranged during Transfection (RET) tyrosine kinase receptor 
resulting in pro-survival signals. GFRA1 belongs to a GDNF receptor family 
comprising of GFR1 – 4 (Carey et al., 2007, Lu et al., 2011). Another study by 
Esseghir and co-workers aimed at identifying transmembrane and secreted 
proteins that are overexpressed in breast cancer tissue and cells provided evidence 
that GDNF may play a role in promoting breast cancer growth by signalling via 
the RET and GFRA1 (Esseghir et al., 2007). A more recent study by Wu and co-
workers investigated the prognostic significance of GFR1, GFR3, Syndecan-3 
and artemin (ARTN) in the survival outcome of breast cancer patients (Wu et al., 
2013). ARTN is up-regulated in cancers and was shown to bind both GFR1 and 
GFR3. The study by Wu and co-workers demonstrated that the co-expression of 
GFR1, GFR3 and ARTN, but not Syndecan-3 was associated with a poor 
patient outcome, such as lymph node metastases and tumour stage (Wu et al., 
2013). There is therefore strong evidence that GFRA1 can be used as a biomarker 
for breast cancer.  
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3.5.1 Future considerations: 
This study identified 4 membrane proteins as possible biomarkers for breast 
cancer. However, only one of these proteins (GFRA1) was investigated by IHC 
expression analysis. Although GeneHub-GEPIS analysis suggested that the other 
3 membrane proteins (NENF, EPHB4 and PTGES2) are not good candidates for 
breast cancer biomarkers, expression analysis by IHC should be done for these 
membrane proteins as well. 
 
Furthermore, even though IHC was performed for GFRA1, it was only done in 
two cell lines (MCF-7 and MCF-12A) and tissue from three breast cancer 
patients. Additional cell lines and a larger number of breast cancer patients should 
be screened. Moreover, tissue from healthy individuals should also be tested. 
 
This study identified 271 CEM proteins that are up-regulated in MCF-7 cells. A 
large number of these proteins were excluded from the study based on the fact that 
these proteins are also expressed in normal breast tissue as demonstrated by the 
GeneHub-GEPIS analysis. However, it is possible that some of these proteins can 
still be used as biomarkers for breast cancer if the expression of these proteins is 
limited to a few tissues and if these proteins are significantly up-regulated breast 
cancer tissue. Further GeneHub-GEPIS analysis and expression analysis of these 
proteins in breast cancer samples should therefore be performed. 
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CHAPTER 4 
 
4.1 Development of a molecular beacon probe for the detection of a breast 
cancer biomarker 
4.1.1 Introduction 
Molecular beacons are single stranded hairpin DNA probes that can be used to 
detect the presence of specific DNA sequences (Yang et al., 2005). As such they 
can be used in the diagnosis of diseases, including breast cancer. The principle of 
detection of specific DNA sequences using molecular beacons is based on a 
fluorescent signal, where the presence of the target DNA sequence result in an 
increase in the fluorescent signal and the absence of the specific DNA sequence 
result in a low fluorescent signal (as demonstrated in Figure 4.1) (Yang et al., 
2005). The molecular beacon consists of a Loop structure that is complementary 
to the specific target DNA sequence, which can be a gene (or biomarker) 
implicated in a disease or genetic material of an infectious organism (a bacterium 
or virus). The Loop structure is flanked on each side by a region of reverse 
complementary DNA sequences (the Stem structure), which has the ability to 
hybridise to each other and form a region of double stranded DNA, the Stem. One 
end of the molecular beacon is conjugated to a fluorescent molecule such as texas 
red or cyanine3 (Cy3), while the other end is conjugated to a quencher molecule 
such as Iowa black or dimethylaminoazobenzen aminoexal-3-acryinido (Dabcyl) 
(Fang et al., 1999, Marras and Salvatore. 2006). In the absence of the target DNA 
sequence, the fluorescent molecule is in close proximity to the quencher molecule 
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because of hybridisation of the Stem structures and as a result the fluorescence 
signal is suppressed. In the presence of the target DNA sequence, the fluorescent 
molecule is separated from the quencher molecule because the target DNA 
sequence hybridise to the Loop structure of the molecular beacon and as a result 
the fluorescence signal is increased. The fluorescent signal typically comes from 
an organic fluorophore such as texas red, cyanine3 (Cy3), fluorescein, etc. As 
pointed out previously, there are a number of limitations when organic 
fluorophores are used in fluorescent diagnostic assays. Some molecular beacon 
studies have been reported where the organic fluorophores have been replaced 
with quantum dots (Bryers et al., 2011). Molecular beacons using quantum dots 
would be more stable and can enable the development of diagnostic systems that 
can detect multiple biomarkers in the same sample. Although, this kind of 
multiplex detection can be done by qRT-PCR, it is very costly, requiring high-end 
instruments and highly trained technicians. Diagnostic assays using molecular 
beacons can be analysed using a plate reader and the cost of the assay would be 
significantly lower compared to qRT-PCR. 
 
It was demonstrated in Chapter 3 by qRT-PCR that the known biomarker for 
breast cancer, CK19 was significantly up-regulated in the breast cancer cell line, 
MCF-7 as compared to the non-cancerous cell line, MCF-12A. The aim in this 
part of the study was to develop a molecular beacon probe for CK19 and to 
investigate the application of this molecular beacon probe to assess the expression 
levels of CK19 in MCF-7 and MCF-12A cells.  
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4.2 Results and Discussion 
4.2.1 Design and development of molecular beacon probe 
Molecular beacon probes consisting of a 20 base pair (bp) region (the Loop 
structure) flanked by either a 5 or 7 bp region (the Stem structure) was designed 
(Figure 4.2) to detect mRNA of the human CK19 gene (ENSG00000171345). The 
Loop structure was a single-stranded DNA oligonucleotide designed based on the 
mRNA sequence for the CK19 gene as described in section 2.8. This single-
stranded DNA oligonucleotide was 20 base pairs long and was complementary to 
region spanning bp 1292 to 1312 of the human CK19 mRNA. BLAST analysis 
against the human genome database was used to confirm the specificity of this 
sequence for the detection of human CK19 mRNA. The undesired hybridization 
and denaturation of the Stem structure due to temperature fluctuations can 
negatively affect the usefulness of the molecular beacon. Therefore two molecular 
beacon probes, one with a Stem of 5 bp (MB-CK19/Short) and one with a Stem of 
7 bp (MB-CK19/Long) were designed. The DNA sequence for the Stem region 
was adapted from the study by (Li et al., 2008), in their study new signal-
amplifying mechanism and nicking enzymes signal amplification (NESA) was 
created to improve the sensitivity of molecular beacons.  
 
The oligonucleotides probes were synthesised at Integrated DNA Technologies. 
The quencher molecule, Iowa Black was coupled to the 5’end of the 
oligonucleotides probes and the 3’end was modified with and amino group as 
described in section 2.8. Qdot525 ITK carboxyl quantum dots were obtained from 
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Life Technologies. These quantum dots (100 pM) were conjugated to the 
oligonucleotides probes (200 nM) as described in section 2.8.2.  
 
 
Figure 4. 1: Illustration of molecular beacon in the presence or absence of target.  
 
 
Figure 4. 2: Design of the molecular beacon probe.   
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4.2.2 Testing the ability of the CK19 molecular beacon probes to detect a 
synthetic complementary DNA sequence 
An oligonucleotide (CK19-Com-Seq) with a sequence that was reverse 
complementary to the Loop structure of the CK19 molecular beacon probe was 
acquired from Integrated DNA Technologies and used as a target sequence for the 
testing of the CK19 molecular beacon probes. This oligonucleotide was used to 
test the ability of the CK19 molecular beacon probes, to detect complementary 
DNA sequences. In addition, this complementary oligonucleotide was also used to 
do a comparative analysis between the effectiveness of a molecular beacon probe 
with a short Stem (MB-CK19/Short) and one with a long Stem (MB-CK19/Long), 
as well as the effect of temperature on the result.  
 
The fluorescence intensity of 10 μM MB-CK19/Short and 10 μM MB-
CK19/Long were measured in the presence and absence of 25 μM CK19-Com-
Seq. MB-CK19/Short and MB-CK19/Long were incubated in the presence and 
absence of CK19-Com-Seq at 60
°
C (the calculated annealing temperature for the 
CK19-Com-Seq to the Loop structure) for 5 min, cooled down to either 20 
°
C or 
25
°
C and the fluorescence intensity was then measured using a POLARstar 
Omega microplate reader as described in section 2.8.3. The calculated annealing 
temperatures for the Stem structure of MB-CK19/Short and MB-CK19/Long was 
20 
°
C and 25 
°
C, respectively and therefore the fluorescence intensities were 
evaluated at both temperatures. Figure 4.3 shows that the fluorescence intensity 
for both MB-CK19/Short and MB-CK19/Long increased significantly in the 
presence of CK19-Com-Seq. In comparison, the fluorescence intensity for MB-
CK19/Short and MB-CK19/Long in the absence of CK19-Com-Seq was very low. 
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This suggested that CK19-Com-Seq binds to the Loop structure of the molecular 
beacons. The p-values for MB-CK19/Short were 0.01668 and 0.000352 at 20 
°
C 
and 25 
°
C, respectively. The p-values for MB-CK19/Long were 0.080285 and 
0.00081 at 20 
°
C and 25 
°
C, respectively. This suggested that 25 
°
C is more 
suitable than 20 
°
C for both MB-CK19/Short and MB-CK19/Long. 
 
No significant difference in the fluorescence intensity between MB-CK19/Short 
and MB-CK19/Long was observed at these temperatures. However, a greater 
degree of variation in the fluorescence intensity was observed for MB-
CK19/Short when compared to MB-CK19/Long. This suggested that MB-
CK19/Long was more stable than MB-CK19/Short.   
 
To determine the lower detection limit of MB-CK19/Short and MB-CK19/Long, 
the fluorescence intensity of these molecular beacons were measured in the 
presence of CK19-Com-Seq at concentrations lower than 25 μM. Figure 4.4 show 
that both MB-CK19/Short and MB-CK19/Long can still detect CK19-Com-Seq at 
concentrations as low as 5 μM. However no significant differences could be 
detected for MB-CK19/Short between the different concentrations. A significant 
difference (p-value = 0.0091) was detected for MB-CK19/Long between 10 to 25 
μM concentrations of CK19-Com-Seq. This suggested that the detection limit for 
MB-CK19/Long was 10 μM.  
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Figure 4. 3: Comparison between MB-CK19/Short and MB-CK19/Long at 20 
°
C and 25 
°
C. The 
fluorescence intensity of MB-CK19/Short and MB-CK19/Long (10 μM) was measured in the 
presence and absence of 25 μM CK19-Com-Seq. Fluorescence intensity was measured using the 
POLAR star Omega Microplate reader. (-) indicate the absence of CK19 complementary, (+) 
indicates the presence of CK19 complementary. n=3. 
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Figure 4. 4: Evaluating the lower detection limit of MB-CK19/Short and MB-CK19/Long. The 
fluorescence intensity of MB-CK19/Short and MB-CK19/Long (10 μM) was measured in the 
presence and absence of 5 μM, 10 μM and 25 μM CK19-Com-Seq. Fluorescence intensity was 
measured using the POLAR star Omega Microplate reader. (-) indicate the absence of CK9 
complementary, (+) indicates the presence of CK19 complementary. n=3. 
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4.2.3 Evaluating the application of MB-CK19/Long to detect CK19 in MCF7 
and MCF-12A samples 
The MB-CK19/Long molecular beacon probe proved to be more stable than the 
MB-CK19/Short probe, as demonstrated in section 4.2.2. To evaluate the 
application of the MB-CK19/Long molecular beacon probe, cDNA samples 
produced from the mRNA isolated from MCF-7 and MCF-12A cells were used as 
the testing material to assess relative expression levels of CK19 in these two cell 
lines.  
 
It was already demonstrated in Chapter 3 that the expression levels of CK19 was 
significantly higher in MCF-7 cells. qRT-PCR analysis demonstrated a 26.895 
fold increase in the expression levels of CK19 in MCF-7 cells in comparison to 
MCF-12A cells. The same cDNA samples that were used in the qRT-PCR 
analysis (section 2.6.3) were used as testing material for the evaluation of the MB-
CK19/Long molecular beacon probe. The fluorescence intensity of 10 μM MB-
CK19/Long was measured in the presence and absence of 10 μM cDNA produced 
from MCF-7 and MCF-12A cells. Figure 4.5 shows a significant (p-value = 
0.0483) increase in the fluorescence intensity of MB-CK19/Long in the presence 
of MCF-7 cDNA. This increase in fluorescence intensity was not observed in the 
presence of MCF-12A cDNA (p-value = 0.418). A significant difference (p-value 
= 0.0462) in the fluorescence intensity for MCF-7 and MCF-12A cDNA was also 
observed. This demonstrated that the MB-CK19/Long molecular beacon probe 
was able to detect CK19 cDNA in a complex samples such as the cDNA library 
prepared from a cell culture. This probe was also able to demonstrate that the 
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expression level of CK19 in MCF-7 cells was higher as compared to MCF-12A 
cells.  
 
This essentially means that the MB-CK19/Long molecular beacon probe can give 
the same result as qRT-PCR analysis, but at a fraction of the cost of the qRT-PCR 
assay. However, the sensitivity of qRT-PCR assay is still significantly higher than 
the molecular beacon probe assay, since much higher concentrations of the cDNA 
were required. In addition, although the assay with the molecular beacon probe 
was able to differentiate between samples with low and high concentrations of the 
target DNA, more research is needed to use this molecular beacon probe 
quantitatively. Since this molecular beacon probe makes use of quantum dots for 
the fluorescence signal, there is a possibility that such molecular beacon probes 
can be used in multiplex diagnostic systems to evaluate the presence of several 
biomarkers in the same sample. As an example, several breast cancer biomarkers 
(e.g. CK19, FOXA1, BRCA2 and HER-2) can be detected in a patient sample 
simultaneously. This can significantly reduce the cost and time of the diagnostic 
assay. 
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Figure 4. 5: Evaluating the expression levels of CK19 in MCF-7 and MCF-12A cDNA libraries 
using MB-CK19/Long. Fluorescence intensity was measured using the POLAR star Omega 
Microplate reader. n=3. (-) indicates the absence of cDNA; (+) indicates the presence cDNA.  
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4.3 Summary and Conclusion: 
This study aimed to develop a molecular beacon probe for the detection of cDNA 
sequences for the breast cancer biomarker, CK19. The molecular probes 
developed here used Iowa Black as the quencher molecule and Qdot525 ITK 
carboxyl quantum dot as the fluorescent molecule.  
 
Two probes (MB-CK19/Short and MB-CK19/Long) were developed to test the 
effects of the Stem length on molecular beacon. A series of control experiments 
using a synthetic oligonucleotide (CK19-Com-Seq) that was complementary to 
the Loop structure of the molecular beacon were performed to test the effects of 
the length of the Stem structure and to determine the lower detection limit of the 
molecular beacon. This study demonstrated that both MB-CK19/Short and MB-
CK19/Long was able to detect the presence of CK19-Com-Seq. The measurement 
of the fluorescence intensity at a temperature of 25 
°
C produced more reliable 
results for both MB-CK19/Short and MB-CK19/Long. The variance in 
fluorescence intensity for MB-CK19/Short was significantly higher compared to 
MB-CK19/Long. This can only be ascribed to the difference in length of the Stem 
structure. This proved that MB-CK19/Long was more suitable than MB-
CK19/Short to detect CK19-Com-Seq. This study also demonstrated that the 
lower detection limit for MB-CK19/Long was 10 μM.  
 
MB-CK19/Long was also used to evaluate presence of CK19 cDNA in a cDNA 
library prepared from MCF-7 and MCF-12A cells. This study showed that MB-
CK19/Long was able to detect the presence of CK19 cDNA in a cDNA library 
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prepared from MCF-7 cells, but not MCF-12A cells. This result is in agreement 
with the qRT-PCR result for CK19, which showed that this gene is over expressed 
in MCF-7 cells. The fact that MB-CK19/Long was able to detect the presence of 
CK19 cDNA in a cDNA library was unexpected since experiments with CK19-
Com-Seq showed that the detection limit for this probe is 10 μM and it is 
expected that the concentration of CK19 cDNA would be much lower than 10 
μM. However, this study does provide evidence that MB-CK19/Long can be used 
to detect CK19 cDNA in a cDNA library. 
 
4.3.1 Future considerations: 
Although this study demonstrates the potential of molecular beacons probes such 
as MB-CK19/Long to detect specific DNA targets, the detection limits of these 
probes are very high and would not be able to detect DNA targets that are 
expressed at low levels. Therefore, the sensitivity of these probes to detect their 
targets should be improved. One possible solution is to use more sensitive 
instrumentation to detect the fluorescence. 
 
Molecular beacon probes such as MB-CK19/Long can potentially lead to the 
development of multiplex detection systems, capable of detecting several breast 
cancer biomarkers in a single sample. This is possible because these probes use 
quantum dots as fluorescence signals. This can be investigated by MB-
CK19/Long in combination with other molecular beacon probes that are designed 
to detect other breast cancer biomarkers such as HER-2, BRCA, FOXA1, etc. 
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CHAPTER 5 
 
5.1 General conclusion 
This study identified 4 putative novel cell surface protein biomarkers (GFRA1, 
NENF, EPHB4 and PTGES2) for the diagnosis of breast cancer. The study 
demonstrated that GFRA1 was significantly overexpressed in a human breast 
cancer cell line (MCF-7) and breast cancer patient tissue. Although the other 3 
genes are also up-regulated in breast cancer cells, the expression levels of these 
genes are not as high as the expression levels of GFRA1. In silico expression 
analysis also shows that although GFRA1 is also over expressed in some other 
types of cancer, the expression levels of this gene is significantly higher breast 
cancer. These biomarkers can potentially be used in the development of POC 
diagnostic systems for the detection of breast cancer. 
 
This study also investigated the development of molecular beacons, which were 
designed using quantum dots as the fluorescent tags, for applications in the 
diagnosis of breast cancer using the known breast cancer biomarker, CK19. The 
data shows that this molecular beacon can distinguish between cDNA samples 
generated from a cancerous (MCF-7) (which overexpress this biomarker) and a 
non-cancerous cell line (MCF-12A).   
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This molecular beacon technology can potentially also be used to develop 
diagnostic tools for the novel biomarkers (GFRA1, NENF, EPHB4 and PTGES2) 
identified in this study. 
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Appendix 
 
Table 1: Reagents utilized in cDNA synthesis reaction in order  
Reagent Final Concentration 
RNA  1 μg 
Anchored-Oligo–p(dT)15 Primer 2.5 μM 
PCR grade water  Variable 
Reaction Buffer 1 X 
RNase Inhibitor  20 U 
Deoxynucleotide Mix  1 mM 
Trancriptor Reverse Transcriptor  10 U 
Total volume  20 μL 
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Table 2: Quantitative real-time PCR cycling parameters. 
 
*Annealing temperature is primer dependent, the range between 57 to 63C 
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Figure 1: Total RNA sample of MCF-7 was analyzed by using bio-analyzer. The 
electropherogram used to obtain RNA integrity Number (RIN).. The RIN value of 9.7 was 
measured for MCF-7.  
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Figure 2: Total RNA sample of MCF-12A was analyzed by using bio-analyzer. The 
electropherogram used to obtain RNA integrity Number (RIN).. The RIN value of 9.7 was 
measured for MCF-12A.  
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Figure 3. GeneHUb-GEPIS charts showing the expression profile of 6 of 10 slected biomarker genes in 40 different tissues. A, B, C, D, E and F shows the 
expression patterns of NRCAM, ABHD12, ENPP1, C12orf10, TEX264 and REEP5 respectively. The blue bar displays the expression in normal tissue and the 
yellow bar shows the expression in tumour tissues. The expression level is represented as a digital expression unit (DEU) values. The expression levels in 
normal and cancerous breast tissue are indicates in a red box. 
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